

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
29 April 2004 (29.04.2004)

PCT

(10) International Publication Number  
**WO 2004/036190 A2**

(51) International Patent Classification<sup>7</sup>: **G01N**

Drive, #10, San Diego, CA 92119 (US). **DARBY, Paul, M.** [US/US]; 8458 Menkar Road, San Diego, CA 92126 (US).

(21) International Application Number:  
PCT/US2003/033639

(22) International Filing Date: 10 October 2003 (10.10.2003)

(74) Agent: **GILLY, Michael, J.**; Gen-Probe Incorporated, Patent Dept., MS #1, 10210 Genetic Center Drive, San Diego, CA 92121-4362 (US).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/418,891 16 October 2002 (16.10.2002) US  
60/429,006 25 November 2002 (25.11.2002) US  
60/449,810 24 February 2003 (24.02.2003) US

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (*for all designated States except US*): **GEN-PROBE INCORPORATED** [US/US]; Patent Dept. MS #1, 10210 Genetic Center Drive, San Diego, CA 92121-4362 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **LINNEN, Jeffrey, M.** [US/US]; 13228 Cooperage Court, Poway, CA 92064 (US). **POLLNER, Reinhold, B.** [DE/US]; 12879 Pine Meadow Court, San Diego, CA 92130 (US). **WU, Wen** [US/US]; 1054 Turnstone Road, Carlsbad, CA 92009 (US). **DENNIS, Geoffrey, G.** [US/US]; 7816 Tommy

Published:

— *without international search report and to be republished upon receipt of that report*

[Continued on next page]

(54) Title: COMPOSITIONS AND METHODS FOR DETECTING WEST NILE VIRUS



(57) Abstract: Compositions, methods and kits for detecting flavivirus nucleic acids. Particularly described are oligonucleotides that are useful as hybridization probes and amplification primers for detecting very low levels of West Nile virus nucleic acids.

WO 2004/036190 A2

BEST AVAILABLE COPY



---

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

## COMPOSITIONS AND METHODS FOR DETECTING WEST NILE VIRUS

### Related Applications

5 This application claims the benefit of U.S. Provisional Application No. 60/418,891, filed October 16, 2002; U.S. Provisional Application No. 60/429,006, filed November 25, 2002; and U.S. Provisional Application No. 60/449,810, filed February 24, 2003. The entire disclosure of these prior applications are hereby incorporated by reference.

### Field of the Invention

10 The present invention relates to the field of biotechnology. More specifically, the invention relates to diagnostic assays for detecting the nucleic acids of flaviviruses, such as West Nile virus.

### Government Interest in Invention

15 Certain aspects of the invention disclosed herein were made with government support under contract N01-HB-07148 with the National Heart, Lung and Blood Institute of the National Institutes of Health. The United States government has certain rights in these aspects of the invention.

### Background of the Invention

20 West Nile virus (WNV) is an RNA virus that primarily infects birds and culex mosquitos, with humans and horses serving as incidental hosts. Amplification of virus in a bird-mosquito-bird cycle begins when adult mosquitos emerge in early spring and continues until fall. This timing coincides with the incidence of disease in humans, which peaks in late summer and early fall. Since it was first detected in New York during 1999, the virus has spread rapidly throughout most of the United States.

25 Indeed, during the first nine months of 2002, a total of more than 2,500 human cases with laboratory evidence of recent WNV infection were reported in 32 states and the District of Columbia. A total of more than 120 human deaths were reported, with the median age of decedents being 79 years. Additionally, there were reports of nearly 5,000 dead crows and nearly 4,000 other dead birds with WNV infection in the United States. Of more than 3,000  
30 mammals detected with WNV infection, greater than 99% were horses. There were also nearly 3,400 WNV-positive mosquito pools reported.

Most human infections with the virus are not clinically apparent. Overall, only 1 in 150

WO 2004/036190  
infections results in severe neurologic illness such as meningitis (inflammation of the spinal cord) or encephalitis (inflammation of the brain). Milder symptoms, which generally last 3 to 6 days and are more commonly reported in connection with WNV infection, include a fever of sudden onset, often accompanied by malaise, anorexia, nausea, vomiting, eye pain, headache, myalgia, rash, and lymphadenopathy. The incubation period of WNV, although not precisely known, probably ranges from 3 to 14 days. An analysis of attack rates per million persons during the 1999 New York City outbreak showed that the incidence of severe neurologic disease was more than 40 times higher in those at least 80 years of age when compared with persons up to 19 years of age. Thus, advanced age is an important risk factor for more severe neurologic disease.

In addition to transmission from mosquitoes, transmission has been linked to blood transfusion and organ transplantation. For example, four recipients of transplanted organs from single donor in the U.S. became infected with West Nile virus in mid-2002. Three of the recipients developed encephalitis, with one of the three dying as a result. The fourth recipient developed mild symptoms of viral infection without encephalitis, but also tested positive for the virus. The organ donor, who was injured in an automobile accident, received numerous transfusions of blood products before dying. She was not known to have been ill before the accident, and a sample of her blood taken before any of the transfusions showed no evidence of West Nile virus. In a separate instance, a nursing mother whose breast milk contained WNV and a male liver transplant patient both received transfused blood from a common donor, and both developed West Nile virus infections. A stored blood sample from that donor tested positive for the WNV, again suggesting a common source of the infectious virus.

West Nile virus is a single-stranded plus-sense RNA virus taxonomically classified in the family *Flaviviridae*, under the genus *Flavivirus*. Accordingly, the virus is a member of the Japanese encephalitis virus serocomplex, which contains several medically important viruses associated with human encephalitis: Japanese encephalitis, St. Louis encephalitis, Murray Valley encephalitis, and Kunjin virus (an Australian subtype of West Nile virus). The viral genome size is approximately 11 kb.

Nucleic acid-based tests for WNV have been described. For example, Shi et al., in *J. Clin. Microbiol.* 39:1264 (2001) have described a real-time polymerase chain reaction (PCR) assay for WNV nucleic acids. Lanciotti et al., in *J. Clin. Microbiol.* 38:4066 (2001) have described a TaqMan-based assay for the detection of WNV RNA in human specimens,

WO 2004/036190  
mosquito pools, and avian tissue specimens. Despite the availability of these PCT/US2003/033639,  
there remains a need for a WNV screening assay that is specifically adapted for the needs of  
clinical testing laboratories. The method should particularly lend itself to high throughput  
screening which may be required for testing large numbers of clinical and donated blood or  
5 tissue samples.

### Summary of the Invention

A first aspect of the invention relates to a hybridization assay probe for detecting a  
nucleic acid. This hybridization assay probe includes a probe sequence that has a target-  
complementary sequence of bases, and optionally one or more base sequences that are not  
10 complementary to the nucleic acid that is to be detected. The target-complementary sequence  
of bases consists of 12-87 contiguous bases contained within the sequence of SEQ ID NO:101  
or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide  
analogues and up to 10%, or even up to 20% base differences. In general, the invented  
hybridization assay probe can have a length of up to 100 bases. In a preferred embodiment, the  
15 target-complementary sequence of bases consists of 12-69 contiguous bases contained within  
the sequence of SEQ ID NO:102 or the complement thereof, allowing for the presence of RNA  
and DNA equivalents, nucleotide analogues and up to 10%, or even up to 20% base differences.  
Still more preferably, the hybridization assay probe includes the optional base sequences that  
are not complementary to the nucleic acid that is to be detected. Even still more preferably, the  
20 hybridization assay probe includes a detectable label. For example, the probe may include a  
fluorophore moiety and a quencher moiety. In such an instance the hybridization assay probe  
can be a molecular beacon. An exemplary molecular beacon can include a target-  
complementary sequence of bases that consists of any one of SEQ ID NO:179, SEQ ID  
NO:180 or SEQ ID NO:181. In accordance with another preferred embodiment of the invented  
25 hybridization assay probe, when the target-complementary sequence of bases consists of 12-69  
contiguous bases contained within the sequence of SEQ ID NO:102 or the complement thereof,  
allowing for the presence of RNA and DNA equivalents, nucleotide analogues and up to 10%, or  
even up to 20% base differences, the probe sequence does not include the optional base  
sequences that are not complementary to the nucleic acid that is to be detected. Still more  
30 preferably, the invented hybridization assay probe has a length of up to 69 bases, and yet still  
more preferably includes a detectable label. In accordance with another preferred embodiment,  
the target-complementary sequence of bases consists of 18-52 contiguous bases contained

WO 2004/036190 PCT/US2003/033639  
within the sequence of SEQ ID NO:103 or the complement thereof, allowing for the presence  
of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base  
differences. Still more preferably, the probe sequence does not include the optional base  
sequences that are not complementary to the nucleic acid that is to be detected, but may further  
include a detectable label. This detectable label can be either a chemiluminescent label or a  
5 fluorescent label. In accordance with an alternative embodiment, the hybridization assay probe  
consists of 18-52 contiguous bases contained within the sequence of SEQ ID NO:103 or the  
complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide  
analogs and up to 10%, or even up to 20% base differences, and has a length of up to 52 bases.  
10 When this is the case, the target-complementary sequence of bases can consist of 18-22  
contiguous bases contained within the sequence of SEQ ID NO:103 or the complement thereof,  
allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or  
even up to 20% base differences, and the hybridization assay probe can have a length of up to  
22 bases. In one embodiment, the invented probe can have the sequence of SEQ ID NO:116.  
15 In another embodiment, the probe sequence can be any of SEQ ID NO:114, SEQ ID NO:111,  
SEQ ID NO:110, SEQ ID NO:109, SEQ ID NO:108, SEQ ID NO:107 or SEQ ID NO:106.

Another aspect of the invention relates to a kit for amplifying a target nucleic acid  
sequence that may be present in a biological sample. The invented kit contains a first primer  
that has a 3' terminal target-complementary sequence and optionally a first primer upstream  
20 sequence that is not complementary to the target nucleic acid sequence that is to be amplified.  
The 3' terminal target-complementary sequence of this first primer includes 22 contiguous  
bases contained within SEQ ID NO:73, allowing for the presence of RNA and DNA  
equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. Also  
included in the kit is a second primer that has a 3' terminal target-complementary sequence and  
25 optionally a second primer upstream sequence that is not complementary to the target nucleic  
acid sequence that is to be amplified. The 3' terminal target-complementary sequence of the  
second primer includes 18 contiguous bases contained within SEQ ID NO:59, allowing for the  
presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20%  
base differences. In a preferred embodiment of the invented kit, the first primer and the second  
30 primer are each up to 60 bases in length. In another preferred embodiment, the 3' terminal  
target-complementary sequence of the first primer and the 3' terminal target-complementary  
sequence of the second primer are each up to 35 bases in length. When this is the case, it is

WO 2004/036190 PCT/US2003/033639  
preferable for the 3' terminal target-complementary sequence of the first primer  
bases in length. Alternatively, and in accordance with yet another preferred embodiment, the 3'  
terminal target-complementary sequence of the first primer can be up to 35 bases in length and  
the 3' terminal target-complementary sequence of the second primer can be up to 22 bases in  
length. When the first primer is up to 24 bases in length, it is highly preferred for the 3'  
terminal target-complementary sequence of the second primer to be up to 22 bases in length.  
Still more preferably, the first primer includes a first primer upstream sequence, such as a  
promoter sequence for T7 RNA polymerase. In accordance with another preferred embodiment  
of the invented kit, when the 3' terminal target-complementary sequence of the first primer is  
up to 24 bases in length, and when the 3' terminal target-complementary sequence of the  
second primer is up to 22 bases in length, the 3' terminal target-complementary sequence of the  
first primer is preferably any of SEQ ID NO:75, SEQ ID NO:76 and SEQ ID NO:77, and the 3'  
terminal target-complementary sequence of the second primer is preferably any of SEQ ID  
NO:60, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66,  
SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:71. In  
accordance with another preferred embodiment, when the 3' terminal target-complementary  
sequence of the first primer is up to 24 bases in length, and when the 3' terminal target-  
complementary sequence of the second primer is up to 35 bases in length, the 3' terminal  
target-complementary sequence of the first primer includes 22 contiguous bases contained  
within SEQ ID NO:74, allowing for the presence of RNA and DNA equivalents, nucleotide  
analogs and up to 10%, or even up to 20% base differences. When this is the case, the 3'  
terminal target-complementary sequence of the second primer can be up to 22 bases in length.  
Alternatively, the first primer may include a first primer upstream sequence, such as a promoter  
sequence for T7 RNA polymerase.

Another aspect of the invention relates to a hybridization assay probe for detecting a  
nucleic acid. The invented hybridization assay probe includes a probe sequence that has a  
target-complementary sequence of bases, and optionally one or more base sequences that are  
not complementary to the nucleic acid that is to be detected. The target-complementary  
sequence of bases consists of 10-20 contiguous bases contained within the sequence of SEQ ID  
NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents,  
nucleotide analogs and up to 10%, or even up to 20% base differences. Finally, the invented  
hybridization assay probe can have a length of up to 100 bases. In a preferred embodiment, the

WO 2004/036190 PCT/US2003/033639  
length of the hybridization assay probe is up to 30 bases. Still more preferably, the probe  
sequence includes the optional base sequences that are not complementary to the nucleic acid  
that is to be detected. In accordance with a first version of this embodiment, there is further  
included a detectable label. In accordance with a second version of this embodiment, there is  
5 further included a fluorophore moiety and a quencher moiety, and the hybridization assay  
probe is a molecular beacon. In a different embodiment, wherein the length of the  
hybridization assay probe is up to 30 bases, the probe sequence consists of 10-20 contiguous  
bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for  
the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to  
0 20% base differences, and does not include the optional base sequences that are not  
complementary to the WNV nucleic acids. More preferably, the hybridization assay probe has  
a length of up to 20 bases. In certain embodiments wherein the length of the hybridization  
assay probe is up to 30 bases, the target-complementary sequence of bases consists of 19-20  
contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof,  
15 allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or  
even up to 20% base differences. In accordance with a first preferred version of this  
embodiment, the probe sequence consists of 19-20 contiguous bases contained within the  
sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and  
DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences, and  
20 does not include the optional base sequences that are not complementary to the nucleic acid  
that is to be detected. In accordance with a second preferred version of this embodiment, the  
hybridization assay probe further includes a detectable label, such as a chemiluminescent label  
or a fluorescent label. In accordance with a third preferred version of this embodiment, the  
target-complementary sequence of bases consists of 19-20 contiguous bases contained within  
25 the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA  
and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences,  
and the hybridization assay probe has a length of up to 20 bases. For example, the probe  
sequence can be SEQ ID NO:100. In accordance with a different embodiment, when the length  
of the hybridization assay probe is up to 30 bases, and when the probe sequence includes the  
30 optional base sequences that are not complementary to the nucleic acid that is to be detected,  
the target-complementary sequence of bases may be any of SEQ ID NO:164, SEQ ID NO:165,  
SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169 or SEQ ID NO:170.



Another aspect of the invention relates to a kit for amplifying a target nucleic acid

sequence that may be present in a biological sample. This kit contains a first primer that includes a 3' terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to the target nucleic acid sequence that is to be amplified.

5 The 3' terminal target-complementary sequence of the first primer includes 22 contiguous bases contained within SEQ ID NO:52, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. The kit further contains a second primer that includes a 3' terminal target-complementary sequence and optionally a

second primer upstream sequence that is not complementary to the target nucleic acid sequence  
0 that is to be amplified. The 3' terminal target-complementary sequence of the second primer includes 22 contiguous bases contained within SEQ ID NO:41, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. In a preferred embodiment, the first primer and the second primer each are up to

60 bases in length. In a different preferred embodiment, the 3' terminal target-complementary  
5 sequence of the first primer and the 3' terminal target-complementary sequence of the second primer are each up to 35 bases in length. When this is the case, the 3' terminal target-complementary sequence of the first primer is preferably up to 26 bases in length. In

accordance with a different preferred embodiment, when the 3' terminal target-complementary  
sequence of the first primer and the 3' terminal target-complementary sequence of the second  
20 primer are each up to 35 bases in length, the 3' terminal target-complementary sequence of the second primer can be up to 23 bases in length. In yet another preferred embodiment, the 3'

terminal target-complementary sequence of the first primer is preferably up to 26 bases in  
length, and the 3' terminal target-complementary sequence of the second primer is up to 23  
bases in length. In accordance with a first preferred version of this embodiment, the 3' terminal

25 target-complementary sequence of the first primer may be selected from the group consisting of SEQ ID NO:53, SEQ ID NO:54 and SEQ ID NO:55, and the 3' terminal target-complementary sequence of the second primer may be selected from the group consisting of SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, and SEQ ID NO:51. In accordance with a second

30 preferred version of this embodiment, the 3' terminal target-complementary sequence of the second primer is up to 23 bases in length. When this is the case, the first primer may include a first primer upstream sequence, such as a promoter sequence for T7 RNA polymerase.

Another aspect of the invention relates to a hybridization assay probe for detecting a

nucleic acid. The invented hybridization assay probe has a probe sequence that includes a target-complementary sequence of bases, and optionally one or more base sequences that are not complementary to the nucleic acid that is to be detected. The target-complementary sequence of bases consists of 13-37 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. Generally speaking, the hybridization assay probe can have a length of up to 100 bases. In a preferred embodiment, the length of the hybridization assay probe is up to 37 bases. More preferably, the hybridization assay probe includes the optional base sequences that are not complementary to the nucleic acid that is to be detected. Still more preferably, the hybridization assay probe further includes a detectable label. For example, the hybridization assay probe may further include a fluorophore moiety and a quencher moiety. In this instance the hybridization assay probe can be a molecular beacon. In a different embodiment of the invented hybridization assay probe, the probe sequence consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences, and does not include the optional base sequences that are not complementary to the nucleic acid that is to be detected. In accordance with still another embodiment, when the length of the hybridization assay probe is up to 37 bases, the target-complementary sequence of bases consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. More preferably, the probe sequence consists of 20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences, and does not include the optional base sequences that are not complementary to the nucleic acid that is to be detected. Still more preferably, the hybridization assay probe further includes a detectable label, such as a chemiluminescent label or a fluorescent label. In accordance with still yet another preferred embodiment, when the length of the hybridization assay probe is up to 37 bases, and when the target-complementary sequence of bases consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to

10%, or even up to 20% base differences, the probe sequence does not include the optional  
base sequences that are not complementary to the nucleic acid that is to be detected, and the  
hybridization assay probe has a length of up to 20 bases. For example, the probe sequence may  
be SEQ ID NO:98. Generally speaking, when the length of the hybridization assay probe is up  
5 to 37 bases, the target-complementary sequence of bases can, for example, be any one of SEQ  
ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, or SEQ ID NO:158.

Another aspect of the invention relates to a kit for amplifying a target nucleic acid  
sequence that may be present in a biological sample. The invented kit contains a first primer  
that includes a 3' terminal target-complementary sequence, and optionally a first primer  
0 upstream sequence that is not complementary to the target nucleic acid sequence that is to be  
amplified. The 3' terminal target-complementary sequence of the first primer includes 20  
contiguous bases contained within SEQ ID NO:16, allowing for the presence of RNA and  
DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. The  
kit further contains a second primer that includes a 3' terminal target-complementary sequence  
5 up to 30 bases in length, and optionally a second primer upstream sequence that is not  
complementary to the target nucleic acid sequence that is to be amplified. The 3' terminal  
target-complementary sequence of the second primer includes 20 contiguous bases contained  
within SEQ ID NO:1, allowing for the presence of RNA and DNA equivalents, nucleotide  
analogs and up to 10%, or even up to 20% base differences. In a preferred embodiment, the  
10 first primer and the second primer are each up to 60 bases in length. In a different preferred  
embodiment, the 3' terminal target-complementary sequence of the first primer is up to 35  
bases in length. In accordance with a first preferred version of this embodiment, the 3' terminal  
target-complementary sequence of the first primer is up to 24 bases in length. In accordance  
with a second preferred version of this embodiment, the 3' terminal target-complementary  
25 sequence of the second primer is up to 24 bases in length. In yet another preferred  
embodiment, when the 3' terminal target-complementary sequence of the first primer is up to  
24 bases in length, the 3' terminal target-complementary sequence of the second primer is  
preferably up to 24 bases in length. In an alternative embodiment, the 3' terminal target-  
complementary sequence of the second primer is up to 26 bases in length and includes 20  
30 contiguous bases contained within SEQ ID NO:2, allowing for the presence of RNA and DNA  
equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences. In  
accordance with a first preferred version of this embodiment, the 3' terminal target-

complementary sequence of the first primer is up to 24 bases in length. In accordance with a second preferred version of this embodiment, the 3' terminal target-complementary sequence of the second primer is up to 24 bases in length. Preferably, the 3' terminal target-complementary sequence of the second primer is up to 24 bases in length. Still more preferably, the 3' terminal target-complementary sequence of the first primer is any one of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:28. In certain embodiments wherein the 3' terminal target-complementary sequence of the first primer is up to 24 bases in length, and the 3' terminal target-complementary sequence of the second primer is up to 26 bases in length and includes 20 contiguous bases contained within SEQ ID NO:2, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10%, or even up to 20% base differences, the 3' terminal target-complementary sequence of the second primer is any one of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15. Alternatively, when the 3' terminal target-complementary sequence of the first primer is any one of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 or SEQ ID NO:28, the 3' terminal target-complementary sequence of the second primer may be any of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14 or SEQ ID NO:15. In accordance with a highly preferred embodiment, the first primer includes the first primer upstream sequence, such as a promoter sequence for T7 RNA polymerase.

#### Definitions

The following terms have the following meanings for the purpose of this disclosure, unless expressly stated to the contrary herein.

As used herein, a "biological sample" is any tissue or polynucleotide-containing material obtained from a human, animal or environmental sample. Biological samples in accordance with the invention include peripheral blood, plasma, serum or other body fluid, bone marrow or other organ, biopsy tissues or other materials of biological origin. A biological sample may be treated to disrupt tissue or cell structure, thereby releasing intracellular components into a solution which may contain enzymes, buffers, salts, detergents and the like.

As used herein, "polynucleotide" means either RNA or DNA, along with any synthetic nucleotide analogs or other molecules that may be present in the sequence and that do not prevent hybridization of the polynucleotide with a second molecule having a complementary sequence.

As used herein, a "detectable label" is a chemical species that can be detected or can

lead to a detectable response. Detectable labels in accordance with the invention can be linked to polynucleotide probes either directly or indirectly, and include radioisotopes, enzymes, haptens, chromophores such as dyes or particles that impart a detectable color (e.g., latex beads or metal particles), luminescent compounds (e.g., bioluminescent, phosphorescent or chemiluminescent moieties) and fluorescent compounds.

A "homogeneous detectable label" refers to a label that can be detected in a homogeneous fashion by determining whether the label is on a probe hybridized to a target sequence. That is, homogeneous detectable labels can be detected without physically removing hybridized from unhybridized forms of the label or labeled probe. Homogeneous detectable labels are preferred when using labeled probes for detecting WNV nucleic acids. Examples of homogeneous labels have been described in detail by Arnold et al., U.S. Patent No. 5,283,174; Woodhead et al., U.S. Patent No. 5,656,207; and Nelson et al., U.S. Patent No. 5,658,737. Preferred labels for use in homogenous assays include chemiluminescent compounds (e.g., see Arnold, Jr., et al., U.S. Patent No. 5,639,604). Preferred chemiluminescent labels are acridinium ester ("AE") compounds, such as standard AE or derivatives thereof (e.g., naphthyl-AE, ortho-AE, 1- or 3-methyl-AE, 2,7-dimethyl-AE, 4,5-dimethyl-AE, ortho-dibromo-AE, ortho-dimethyl-AE, meta-dimethyl-AE, ortho-methoxy-AE, ortho-methoxy(cinnamyl)-AE, ortho-methyl-AE, ortho-fluoro-AE, 1- or 3-methyl-ortho-fluoro-AE, 1- or 3-methyl-meta-difluoro-AE, and 2-methyl-AE).

A "homogeneous assay" refers to a detection procedure that does not require physical separation of hybridized probe from non-hybridized probe prior to determining the extent of specific probe hybridization. Exemplary homogeneous assays, such as those described herein, can employ molecular beacons or other self-reporting probes which emit fluorescent signals when hybridized to an appropriate target, chemiluminescent acridinium ester labels which can be selectively destroyed by chemical means unless present in a hybrid duplex, and other homogeneously detectable labels that will be familiar to those having an ordinary level of skill in the art.

As used herein, "amplification" refers to an *in vitro* procedure for obtaining multiple copies of a target nucleic acid sequence, its complement or fragments thereof.

By "target nucleic acid" or "target" is meant a nucleic acid containing a target nucleic acid sequence. In general, a target nucleic acid sequence that is to be amplified will be

WO 2004/036190 PCT/US2003/033639  
positioned between two oppositely disposed primers, and will include the portion of the target  
nucleic acid that is fully complementary to each of the primers.

By "target nucleic acid sequence" or "target sequence" or "target region" is meant a  
specific deoxyribonucleotide or ribonucleotide sequence comprising all or part of the  
5 nucleotide sequence of a single-stranded nucleic acid molecule, and the deoxyribonucleotide or  
ribonucleotide sequence complementary thereto.

By "transcription associated amplification" is meant any type of nucleic acid  
amplification that uses an RNA polymerase to produce multiple RNA transcripts from a  
nucleic acid template. One example of a transcription associated amplification method, called  
0 "Transcription Mediated Amplification" (TMA), generally employs an RNA polymerase, a  
DNA polymerase, deoxyribonucleoside triphosphates, ribonucleoside triphosphates, and a  
promoter-template complementary oligonucleotide, and optionally may include one or more  
analogous oligonucleotides. Variations of TMA are well known in the art as disclosed in detail  
in Burg et al., U.S. Patent No. 5,437,990; Kacian et al., U.S. Patent Nos. 5,399,491 and  
5 5,554,516; Kacian et al., PCT No. WO 93/22461; Gingeras et al., PCT No. WO 88/01302;  
Gingeras et al., PCT No. WO 88/10315; Malek et al., U.S. Patent No. 5,130,238; Urdea et al.,  
U.S. Patent Nos. 4,868,105 and 5,124,246; McDonough et al., PCT No. WO 94/03472; and  
Ryder et al., PCT No. WO 95/03430. The methods of Kacian et al. are preferred for  
conducting nucleic acid amplification procedures of the type disclosed herein.

10 As used herein, an "oligonucleotide" or "oligomer" is a polymeric chain of at least two,  
generally between about five and about 100, chemical subunits, each subunit comprising a  
nucleotide base moiety, a sugar moiety, and a linking moiety that joins the subunits in a linear  
spacial configuration. Common nucleotide base moieties are guanine (G), adenine (A),  
cytosine (C), thymine (T) and uracil (U), although other rare or modified nucleotide bases able  
25 to hydrogen bond are well known to those skilled in the art. Oligonucleotides may optionally  
include analogs of any of the sugar moieties, the base moieties, and the backbone constituents.  
Preferred oligonucleotides of the present invention fall in a size range of about 10 to about 100  
residues. Oligonucleotides may be purified from naturally occurring sources, but preferably  
are synthesized using any of a variety of well known enzymatic or chemical methods.

30 As used herein, a "probe" is an oligonucleotide that hybridizes specifically to a target  
sequence in a nucleic acid, preferably in an amplified nucleic acid, under conditions that  
promote hybridization, to form a detectable hybrid. A probe optionally may contain a

The nucleotides of the probe which combine with the target polynucleotide need not be strictly contiguous, as may be the case with a detectable moiety internal to the sequence of the probe. Detection may either be direct (i.e., resulting from a probe hybridizing directly to the target sequence or amplified nucleic acid) or indirect (i.e., resulting from a probe hybridizing to an intermediate molecular structure that links the probe to the target sequence or amplified nucleic acid). The "target" of a probe generally refers to a sequence contained within an amplified nucleic acid sequence which hybridizes specifically to at least a portion of a probe oligonucleotide using standard hydrogen bonding (i.e., base pairing). A probe may comprise target-specific sequences and optionally other sequences that are non-complementary to the target sequence that is to be detected. These non-complementary sequences may comprise a promoter sequence, a restriction endonuclease recognition site, or sequences that contribute to three-dimensional conformation of the probe (e.g., as described in Lizardi et al., U.S. Patent Nos. 5,118,801 and 5,312,728). Sequences that are "sufficiently complementary" allow stable hybridization of a probe oligonucleotide to a target sequence that is not completely complementary to the probe's target-specific sequence.

As used herein, an "amplification primer" is an oligonucleotide that hybridizes to a target nucleic acid, or its complement, and participates in a nucleic acid amplification reaction. For example, amplification primers, or more simply "primers," may be optionally modified oligonucleotides which are capable of hybridizing to a template nucleic acid and which have a 3' end that can be extended by a DNA polymerase activity. In general, a primer will have a downstream WNV-complementary sequence, and optionally an upstream sequence that is not complementary to WNV nucleic acids. The optional upstream sequence may, for example, serve as an RNA polymerase promoter or contain restriction endonuclease cleavage sites.

By "substantially homologous," "substantially corresponding" or "substantially corresponds" is meant that the subject oligonucleotide has a base sequence containing an at least 10 contiguous base region that is at least 70% homologous, preferably at least 80% homologous, more preferably at least 90% homologous, and most preferably 100% homologous to an at least 10 contiguous base region present in a reference base sequence (excluding RNA and DNA equivalents). Those skilled in the art will readily appreciate modifications that could be made to the hybridization assay conditions at various percentages of homology to permit hybridization of the oligonucleotide to the target sequence while

WO 2004/036190 PCT/US2003/033639  
preventing unacceptable levels of non-specific hybridization. The degree of similarity is  
determined by comparing the order of nucleobases making up the two sequences and does not  
take into consideration other structural differences which may exist between the two sequences,  
provided the structural differences do not prevent hydrogen bonding with complementary  
5 bases. The degree of homology between two sequences can also be expressed in terms of the  
number of base mismatches present in each set of at least 10 contiguous bases being compared,  
which may range from 0-2 base differences.

By "substantially complementary" is meant that the subject oligonucleotide has a base  
sequence containing an at least 10 contiguous base region that is at least 70% complementary,  
0 preferably at least 80% complementary, more preferably at least 90% complementary, and  
most preferably 100% complementary to an at least 10 contiguous base region present in a  
target nucleic acid sequence (excluding RNA and DNA equivalents). (Those skilled in the art  
will readily appreciate modifications that could be made to the hybridization assay conditions  
at various percentages of complementarity to permit hybridization of the oligonucleotide to the  
5 target sequence while preventing unacceptable levels of non-specific hybridization.) The  
degree of complementarity is determined by comparing the order of nucleobases making up the  
two sequences and does not take into consideration other structural differences which may exist  
between the two sequences, provided the structural differences do not prevent hydrogen  
bonding with complementary bases. The degree of complementarity between two sequences  
20 can also be expressed in terms of the number of base mismatches present in each set of at least  
10 contiguous bases being compared, which may range from 0-2 base mismatches.

By "sufficiently complementary" is meant a contiguous nucleic acid base sequence that  
is capable of hybridizing to another base sequence by hydrogen bonding between a series of  
complementary bases. Complementary base sequences may be complementary at each position  
25 in the base sequence of an oligonucleotide using standard base pairing (e.g., G:C, A:T or A:U  
pairing) or may contain one or more residues that are not complementary using standard  
hydrogen bonding (including abasic "nucleotides"), but in which the entire complementary  
base sequence is capable of specifically hybridizing with another base sequence under  
appropriate hybridization conditions. Contiguous bases are preferably at least about 80%, more  
30 preferably at least about 90%, and most preferably about 100% complementary to a sequence  
to which an oligonucleotide is intended to specifically hybridize. Appropriate hybridization  
conditions are well known to those skilled in the art, can be predicted readily based on base



6, WO 2004/036190  
sequence composition, or can be determined empirically by using routine testing (e.g., Sambrook et al., Molecular Cloning, A Laboratory Manual, 2<sup>nd</sup> ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989) at §§ 1.90-1.91, 7.37-7.57, 9.47-9.51 and 11.47-11.57 particularly at §§ 9.50-9.51, 11.12-11.13, 11.45-11.47 and 11.55-11.57).

5 By "capture oligonucleotide" is meant at least one nucleic acid oligonucleotide that provides means for specifically joining a target sequence and an immobilized oligonucleotide due to base pair hybridization. A capture oligonucleotide preferably includes two binding regions: a target sequence-binding region and an immobilized probe-binding region, usually contiguous on the same oligonucleotide, although the capture oligonucleotide may include a  
10 target sequence-binding region and an immobilized probe-binding region which are present on two different oligonucleotides joined together by one or more linkers. For example, an immobilized probe-binding region may be present on a first oligonucleotide, the target sequence-binding region may be present on a second oligonucleotide, and the two different oligonucleotides are joined by hydrogen bonding with a linker that is a third oligonucleotide  
15 containing sequences that hybridize specifically to the sequences of the first and second oligonucleotides.

By "immobilized probe" or "immobilized nucleic acid" is meant a nucleic acid that joins, directly or indirectly, a capture oligonucleotide to an immobilized support. An immobilized probe is an oligonucleotide joined to a solid support that facilitates separation of  
20 bound target sequence from unbound material in a sample.

By "separating" or "purifying" is meant that one or more components of the biological sample are removed from one or more other components of the sample. Sample components include nucleic acids in a generally aqueous solution phase which may also include materials such as proteins, carbohydrates, lipids and labeled probes. Preferably, the separating or  
25 purifying step removes at least about 70%, more preferably at least about 90% and, even more preferably, at least about 95% of the other components present in the sample.

By "RNA and DNA equivalents" or "RNA and DNA equivalent bases" is meant molecules, such as RNA and DNA, having the same complementary base pair hybridization properties. RNA and DNA equivalents have different sugar moieties (i.e., ribose versus  
30 deoxyribose) and may differ by the presence of uracil in RNA and thymine in DNA. The differences between RNA and DNA equivalents do not contribute to differences in homology because the equivalents have the same degree of complementarity to a particular sequence.

By "consisting essentially of" is meant that additional component(s), composition(s) or method step(s) that do not materially change the basic and novel characteristics of the present invention may be included in the compositions or kits or methods of the present invention. Such characteristics include the ability to selectively detect WNV nucleic acids in biological samples such as whole blood or plasma. Any component(s), composition(s), or method step(s) that have a material effect on the basic and novel characteristics of the present invention would fall outside of this term.

#### Brief Description of the Drawings

Figure 1 is a schematic diagram illustrating the various polynucleotides that can be used for detecting a target region within the WNV nucleic acid (represented by a thick horizontal line). Positions of the following nucleic acids are shown relative to the target region: "Capture Oligonucleotide" refers to the nucleic acid used to hybridize to and capture the target nucleic acid prior to amplification, where "T" refers to a tail sequence used to hybridize an immobilized oligonucleotide having a complementary sequence (not shown); "Non-T7 Primer" and "T7 Promoter-Primer" represent two amplification primers used for conducting TMA, where "P" indicates the promoter sequence of the T7 promoter-primer; and "Probe" refers to the probe used for detecting amplified nucleic acid.

Figure 2 shows a series of line graphs representing specific probe hybridization signals, measured in relative light units (y-axis) versus increasing levels of input target (x-axis). The target oligonucleotides used in the procedure had the sequences of SEQ ID NO:148 (●), SEQ ID NO:150 (◆), SEQ ID NO:151 (■), and SEQ ID NO:152 (▲).

Figure 3 is a line graph relating the amount of WNV standard input into a real-time nucleic acid amplification reaction (x-axis) and the time-of-emergence of the measured fluorescent signal above a background threshold (y-axis).

#### Detailed Description of the Invention

Disclosed herein are compositions, methods and kits for selectively detecting the nucleic acids of flaviviruses, such as West Nile virus (WNV), in biological samples such as blood, serum, plasma or other body fluid or tissue. The probes, primers and methods of the invention can be used either in diagnostic applications or for screening donated blood and blood products or other tissues that may contain infectious particles.

#### Introduction and Overview

The present invention includes compositions (nucleic acid capture oligonucleotides,

WO 2004/036190 PCT/US2003/033639  
amplification oligonucleotides and probes), methods and kits that are particularly useful for  
detecting WNV nucleic acids in a biological sample. To design oligonucleotide sequences  
appropriate for such uses, known WNV nucleic acid sequences were first compared to identify  
candidate regions of the viral genome that could serve as reagents in a diagnostic assay. As a  
5 result of these comparisons, three different regions of the WNV genome were selected as  
targets for detection using the capture oligonucleotides, primers and probes shown  
schematically in Figure 1. Portions of sequences containing relatively few variants between the  
compared sequences were chosen as starting points for designing synthetic oligonucleotides  
suitable for use in capture, amplification and detection of amplified sequences.

0 Based on these analyses, the capture oligonucleotide, amplification primer and probe  
sequences presented below were designed. Those having an ordinary level of skill in the art  
will appreciate that any primer sequences specific for WNV or other flavivirus target, with or  
without a T7 promoter sequence, may be used as primers in the various primer-based *in vitro*  
amplification methods described below. It is also contemplated that oligonucleotides having  
5 the sequences disclosed herein could serve alternative functions in assays for detecting WNV  
nucleic acids. For example, the capture oligonucleotides disclosed herein could serve as  
hybridization probes, the hybridization probes disclosed herein could be used as amplification  
primers, and the amplification primers disclosed herein could be used as hybridization probes  
in alternative detection assays.

10 The amplification primers disclosed herein are particularly contemplated as components  
of multiplex amplification reactions wherein several amplicon species can be produced from an  
assortment of target-specific primers. For example, it is contemplated that certain preferred  
WNV-specific primers disclosed herein can be used in multiplex amplification reactions that  
are capable of amplifying polynucleotides of unrelated viruses without substantially  
25 compromising the sensitivities of those assays. Particular examples of these unrelated viruses  
include HIV-1, HIV-2, HCV and HBV.

#### Useful Amplification Methods

Amplification methods useful in connection with the present invention include:  
Transcription Mediated Amplification (TMA), Nucleic Acid Sequence-Based Amplification  
30 (NASBA), the Polymerase Chain Reaction (PCR), Strand Displacement Amplification (SDA),  
and amplification methods using self-replicating polynucleotide molecules and replication  
enzymes such as MDV-1 RNA and Q-beta enzyme. Methods for carrying out these various

WO 2004/036190  
amplification techniques respectively can be found in U.S. Patent No. 5,399,411, PCT/US2003/033639  
European patent application EP 0 525 882, U.S. Patent No. 4,965,188, U.S. Patent No.  
5,455,166, U.S. Patent No. 5,472,840 and Lizardi et al., *BioTechnology* 6:1197 (1988). The  
disclosures of these documents which describe how to perform nucleic acid amplification  
reactions are hereby incorporated by reference.

In a highly preferred embodiment of the invention, WNV nucleic acid sequences are  
amplified using a TMA protocol. According to this protocol, the reverse transcriptase which  
provides the DNA polymerase activity also possesses an endogenous RNase H activity. One of  
the primers used in this procedure contains a promoter sequence positioned upstream of a  
sequence that is complementary to one strand of a target nucleic acid that is to be amplified. In  
the first step of the amplification, a promoter-primer hybridizes to the WNV target RNA at a  
defined site. Reverse transcriptase creates a complementary DNA copy of the target RNA by  
extension from the 3' end of the promoter-primer. Following interaction of an opposite strand  
primer with the newly synthesized DNA strand, a second strand of DNA is synthesized from  
the end of the primer by reverse transcriptase, thereby creating a double-stranded DNA  
molecule. RNA polymerase recognizes the promoter sequence in this double-stranded DNA  
template and initiates transcription. Each of the newly synthesized RNA amplicons re-enters  
the TMA process and serves as a template for a new round of replication, thereby leading to an  
exponential expansion of the RNA amplicon. Since each of the DNA templates can make 100-  
1000 copies of RNA amplicon, this expansion can result in the production of 10 billion  
amplicons in less than one hour. The entire process is autocatalytic and is performed at a  
constant temperature.

#### Structural Features of Primers

As indicated above, a "primer" refers to an optionally modified oligonucleotide which  
is capable of participating in a nucleic acid amplification reaction. Preferred primers are  
capable of hybridizing to a template nucleic acid and which has a 3' end that can be extended  
by a DNA polymerase activity. The 5' region of the primer may be non-complementary to the  
target nucleic acid. If the 5' non-complementary region includes a promoter sequence, it is  
referred to as a "promoter-primer." Those skilled in the art will appreciate that any  
oligonucleotide that can function as a primer (i.e., an oligonucleotide that hybridizes  
specifically to a target sequence and has a 3' end capable of extension by a DNA polymerase  
activity) can be modified to include a 5' promoter sequence, and thus could function as a

WO 2004/036190. Similarly, any promoter-primer can be modified by removal or, or synthesis  
without, a promoter sequence and still function as a primer.

Nucleotide base moieties of primers may be modified (e.g., by the addition of propyne groups), as long as the modified base moiety retains the ability to form a non-covalent association with G, A, C, T or U, and as long as an oligonucleotide comprising at least one modified nucleotide base moiety or analog is not sterically prevented from hybridizing with a single-stranded nucleic acid. As indicated below in connection with the chemical composition of useful probes, the nitrogenous bases of primers in accordance with the invention may be conventional bases (A, G, C, T, U), known analogs thereof (e.g., inosine or "I" having hypoxanthine as its base moiety; see The Biochemistry of the Nucleic Acids 5-36, Adams et al., ed., 11<sup>th</sup> ed., 1992), known derivatives of purine or pyrimidine bases (e.g., N<sup>4</sup>-methyl deoxygaunosine, deaza- or aza-purines and deaza- or aza-pyrimidines, pyrimidine bases having substituent groups at the 5 or 6 position, purine bases having an altered or a replacement substituent at the 2, 6 or 8 positions, 2-amino-6-methylaminopurine, O<sup>6</sup>-methylguanine, 4-thio-pyrimidines, 4-amino-pyrimidines, 4-dimethylhydrazine-pyrimidines, and O<sup>4</sup>-alkyl-pyrimidines (see, Cook, PCT Int'l Pub. No, WO 93/13121) and "abasic" residues where the backbone includes no nitrogenous base for one or more residues of the polymer (see Arnold et al., U.S. Patent No. 5,585,481). Common sugar moieties that comprise the primer backbone include ribose and deoxyribose, although 2'-O-methyl ribose (OMe), halogenated sugars, and other modified sugar moieties may also be used. Usually, the linking group of the primer backbone is a phosphorus-containing moiety, most commonly a phosphodiester linkage, although other linkages, such as, for example, phosphorothioates, methylphosphonates, and non-phosphorus-containing linkages such as peptide-like linkages found in "peptide nucleic acids" (PNA) also are intended for use in the assay disclosed herein.

#### Useful Probe Labeling Systems and Detectable Moieties

Essentially any labeling and detection system that can be used for monitoring specific nucleic acid hybridization can be used in conjunction with the present invention. Included among the collection of useful labels are radiolabels, enzymes, haptens, linked oligonucleotides, chemiluminescent molecules, fluorescent moieties (either alone or in combination with "quencher" moieties), and redox-active moieties that are amenable to electronic detection methods. Preferred chemiluminescent molecules include acridinium esters of the type disclosed by Arnold et al., in U.S. Patent No. 5,283,174 for use in connection with

homogeneous protection assays, and of the type disclosed by Woodhead et al., in U.S. Patent  
No. 5,656,207 for use in connection with assays that quantify multiple targets in a single  
reaction. The disclosures contained in these patent documents are hereby incorporated by  
reference. Preferred electronic labeling and detection approaches are disclosed in U.S. Patent  
Nos. 5,591,578 and 5,770,369, and the published international patent application WO  
98/57158, the disclosures of which are hereby incorporated by reference. Redox active  
moieties useful as labels in the present invention include transition metals such as Cd, Mg, Cu,  
Co, Pd, Zn, Fe and Ru.

Particularly preferred detectable labels for probes in accordance with the present  
invention are detectable in homogeneous assay systems (i.e., where, in a mixture, bound  
labeled probe exhibits a detectable change, such as stability or differential degradation,  
compared to unbound labeled probe). While other homogeneously detectable labels, such as  
fluorescent labels and electronically detectable labels, are intended for use in the practice of the  
present invention, a preferred label for use in homogenous assays is a chemiluminescent  
compound (e.g., as described by Woodhead et al., in U.S. Patent No. 5,656,207; by Nelson et  
al., in U.S. Patent No. 5,658,737; or by Arnold et al., in U.S. Patent No. 5,639,604).  
Particularly preferred chemiluminescent labels include acridinium ester ("AE") compounds,  
such as standard AE or derivatives thereof, such as naphthyl-AE, ortho-AE, 1- or 3-methyl-AE,  
2,7-dimethyl-AE, 4,5-dimethyl-AE, ortho-dibromo-AE, ortho-dimethyl-AE, meta-dimethyl-  
AE, ortho-methoxy-AE, ortho-methoxy(cinnamyl)-AE, ortho-methyl-AE, ortho-fluoro-AE, 1-  
or 3-methyl-ortho-fluoro-AE, 1- or 3-methyl-meta-difluoro-AE, and 2-methyl-AE.

In some applications, probes exhibiting at least some degree of self-complementarity  
are desirable to facilitate detection of probe:target duplexes in a test sample without first  
requiring the removal of unhybridized probe prior to detection. By way of example, structures  
referred to as "Molecular Torches" are designed to include distinct regions of self-  
complementarity (coined "the target binding domain" and "the target closing domain") which  
are connected by a joining region and which hybridize to one another under predetermined  
hybridization assay conditions. When exposed to denaturing conditions, the two  
complementary regions (which may be fully or partially complementary) of the Molecular  
Torch melt, leaving the target binding domain available for hybridization to a target sequence  
when the predetermined hybridization assay conditions are restored. Molecular Torches are  
designed so that the target binding domain favors hybridization to the target sequence over the

WO 2004/036190 PCT/US2003/033639  
target closing domain. The target binding domain and the target closing domain of a Molecular Torch include interacting labels (e.g., fluorescent/quencher) positioned so that a different signal is produced when the Molecular Torch is self-hybridized as opposed to when the Molecular Torch is hybridized to a target nucleic acid, thereby permitting detection of probe:target  
5 duplexes in a test sample in the presence of unhybridized probe having a viable label associated therewith. Molecular Torches are fully described in U.S. Patent No. 6,361,945, the disclosure of which is hereby incorporated by reference.

Another example of a self-complementary hybridization assay probe that may be used in conjunction with the invention is a structure commonly referred to as a "Molecular Beacon."  
10 Molecular Beacons comprise nucleic acid molecules having a target complementary sequence, an affinity pair (or nucleic acid arms) holding the probe in a closed conformation in the absence of a target nucleic acid sequence, and a label pair that interacts when the probe is in a closed conformation. Hybridization of the target nucleic acid and the target complementary sequence separates the members of the affinity pair, thereby shifting the probe to an open conformation.  
15 The shift to the open conformation is detectable due to reduced interaction of the label pair, which may be, for example, a fluorophore and a quencher (e.g., DABCYL and EDANS). Molecular Beacons are fully described in U.S. Patent No. 5,925,517, the disclosure of which is hereby incorporated by reference. Molecular beacons useful for detecting WNV-specific nucleic acid sequences may be created by appending to either end of one of the probe  
20 sequences disclosed herein, a first nucleic acid arm comprising a fluorophore and a second nucleic acid arm comprising a quencher moiety. In this configuration, the WNV-specific probe sequence disclosed herein serves as the target-complementary "loop" portion of the resulting molecular beacon.

Molecular beacons preferably are labeled with an interactive pair of detectable labels.  
25 Examples of detectable labels that are preferred as members of an interactive pair of labels interact with each other by FRET or non-FRET energy transfer mechanisms. Fluorescence resonance energy transfer (FRET) involves the radiationless transmission of energy quanta from the site of absorption to the site of its utilization in the molecule, or system of molecules, by resonance interaction between chromophores, over distances considerably greater than  
30 interatomic distances, without conversion to thermal energy, and without the donor and acceptor coming into kinetic collision. The "donor" is the moiety that initially absorbs the energy, and the "acceptor" is the moiety to which the energy is subsequently transferred. In

WO 2004/036190 PCT/US2003/033639  
addition to FRET, there are at least three other "non-FRET" energy transfer processes by which  
excitation energy can be transferred from a donor to an acceptor molecule.

When two labels are held sufficiently close that energy emitted by one label can be  
received or absorbed by the second label, whether by a FRET or non-FRET mechanism, the  
two labels are said to be in "energy transfer relationship" with each other. This is the case, for  
example, when a molecular beacon is maintained in the closed state by formation of a stem  
duplex, and fluorescent emission from a fluorophore attached to one arm of the probe is  
quenched by a quencher moiety on the opposite arm.

Highly preferred label moieties for the invented molecular beacons include a  
fluorophore and a second moiety having fluorescence quenching properties (i.e., a "quencher").  
In this embodiment, the characteristic signal is likely fluorescence of a particular wavelength,  
but alternatively could be a visible light signal. When fluorescence is involved, changes in  
emission are preferably due to FRET, or to radiative energy transfer or non-FRET modes.  
When a molecular beacon having a pair of interactive labels in the closed state is stimulated by  
an appropriate frequency of light, a fluorescent signal is generated at a first level, which may be  
very low. When this same probe is in the open state and is stimulated by an appropriate  
frequency of light, the fluorophore and the quencher moieties are sufficiently separated from  
each other that energy transfer between them is substantially precluded. Under that condition,  
the quencher moiety is unable to quench the fluorescence from the fluorophore moiety. If the  
fluorophore is stimulated by light energy of an appropriate wavelength, a fluorescent signal of a  
second level, higher than the first level, will be generated. The difference between the two  
levels of fluorescence is detectable and measurable. Using fluorophore and quencher moieties  
in this manner, the molecular beacon is only "on" in the "open" conformation and indicates that  
the probe is bound to the target by emanating an easily detectable signal. The conformational  
state of the probe alters the signal generated from the probe by regulating the interaction  
between the label moieties.

Examples of donor/acceptor label pairs that may be used in connection with the  
invention, making no attempt to distinguish FRET from non-FRET pairs, include  
fluorescein/tetramethylrhodamine, IAEDANS/fluorescein, EDANS/DABCYL,  
coumarin/DABCYL, fluorescein/fluorescein, BODIPY FL/BODIPY FL,  
fluorescein/DABCYL, lucifer yellow/DABCYL, BODIPY/DABCYL, eosine/DABCYL,  
erythrosine/DABCYL, tetramethylrhodamine/DABCYL, Texas Red/DABCYL, CY5/BH1,



WO 2004/036190 PCT/US2003/033639  
CY5/BH2, CY3/BH1, CY3/BH2 and fluorescein/QSY7 dye. Those having an ordinary level of skill in the art will understand that when donor and acceptor dyes are different, energy transfer can be detected by the appearance of sensitized fluorescence of the acceptor or by quenching of donor fluorescence. When the donor and acceptor species are the same, energy can be detected by the resulting fluorescence depolarization. Non-fluorescent acceptors such as DABCYL and the QSY 7 dyes advantageously eliminate the potential problem of background fluorescence resulting from direct (i.e., non-sensitized) acceptor excitation. Preferred fluorophore moieties that can be used as one member of a donor-acceptor pair include fluorescein, ROX, and the CY dyes (such as CY5). Highly preferred quencher moieties that can be used as another member of a donor-acceptor pair include DABCYL and the BLACK HOLE QUENCHER moieties which are available from Biosearch Technologies, Inc., (Novato, CA).

Synthetic techniques and methods of bonding labels to nucleic acids and detecting labels are well known in the art (e.g., see Sambrook et al., Molecular Cloning. A Laboratory Manual, 2nd ed. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1989), Chapter 10; Nelson et al., U.S. Patent No. 5,658,737; Woodhead et al., U.S. Patent No. 5,656,207; Hogan et al., U.S. Patent No. 5,547,842; Arnold et al., U.S. Patent No. 5,283,174; Kourilsky et al., U.S. Patent No. 4,581,333), and Becker et al., European Patent App. No. 0 747 706.

#### Chemical Composition of Probes

Probes in accordance with the invention comprise polynucleotides or polynucleotide analogs and optionally may carry a detectable label covalently bonded thereto. Nucleosides or nucleoside analogs of the probe comprise nitrogenous heterocyclic bases, or base analogs, where the nucleosides are linked together, for example by phosphodiester bonds to form a polynucleotide. Accordingly, a probe may comprise conventional ribonucleic acid (RNA) and/or deoxyribonucleic acid (DNA), but also may comprise chemical analogs of these molecules. The "backbone" of a probe may be made up of a variety of linkages known in the art, including one or more sugar-phosphodiester linkages, peptide-nucleic acid bonds (sometimes referred to as "peptide nucleic acids" as described by Hyldig-Nielsen et al., PCT Int'l Pub. No. WO 95/32305), phosphorothioate linkages, methylphosphonate linkages or combinations thereof. Sugar moieties of the probe may be either ribose or deoxyribose, or similar compounds having known substitutions, such as, for example, 2'-O-methyl ribose and 2' halide substitutions (e.g., 2'-F). The nitrogenous bases may be conventional bases (A, G, C, T,

WO 2004/036190 PCT/US2003/033639  
U), known analogs thereof (e.g., inosine or "I"; see The Biochemistry of the Nucleic Acids 36, Adams et al., ed., 11<sup>th</sup> ed., 1992), known derivatives of purine or pyrimidine bases (e.g., N<sup>4</sup>-methyl deoxygaunosine, deaza- or aza-purines and deaza- or aza-pyrimidines, pyrimidine bases having substituent groups at the 5 or 6 position, purine bases having an altered or a replacement substituent at the 2, 6 or 8 positions, 2-amino-6-methylaminopurine, O<sup>6</sup>-methylguanine, 4-thio-pyrimidines, 4-amino-pyrimidines, 4-dimethylhydrazine-pyrimidines, and O<sup>4</sup>-alkyl-pyrimidines (see, Cook, PCT Int'l Pub. No. WO 93/13121) and "abasic" residues where the backbone includes no nitrogenous base for one or more residues of the polymer (see Arnold et al., U.S. Patent No. 5,585,481). A probe may comprise only conventional sugars, bases and linkages found in RNA and DNA, or may include both conventional components and substitutions (e.g., conventional bases linked via a methoxy backbone, or a nucleic acid including conventional bases and one or more base analogs).

While oligonucleotide probes of different lengths and base composition may be used for detecting WNV nucleic acids, preferred probes in this invention have lengths of up to 100 nucleotides, and more preferably have lengths of up to 60 nucleotides. Preferred length ranges for the invented oligonucleotides are from 10 to 100 bases in length, or more preferably between 15 and 50 bases in length, or still more preferably between 15 and 30 bases in length. However, the specific probe sequences described below also may be provided in a nucleic acid cloning vector or transcript or other longer nucleic acid and still can be used for detecting WNV nucleic acids.

#### Selection of Amplification Primers and Detection Probes Specific for WNV

Useful guidelines for designing amplification primers and probes with desired characteristics are described herein. The optimal sites for amplifying and probing WNV nucleic acids contain two, and preferably three, conserved regions each greater than about 15 bases in length, within about 200 bases of contiguous sequence. The degree of amplification observed with a set of primers or promoter-primers depends on several factors, including the ability of the oligonucleotides to hybridize to their complementary sequences and their ability to be extended enzymatically. Because the extent and specificity of hybridization reactions are affected by a number of factors, manipulation of those factors will determine the exact sensitivity and specificity of a particular oligonucleotide, whether perfectly complementary to its target or not. The effects of varying assay conditions are known to those skilled in the art, and are described by Hogan et al., in U.S. Patent No. 5,840,488, the disclosure of which is

The length of the target nucleic acid sequence and, accordingly, the length of the primer sequence or probe sequence can be important. In some cases, there may be several sequences from a particular target region, varying in location and length, which will yield primers or probes having the desired hybridization characteristics. While it is possible for nucleic acids that are not perfectly complementary to hybridize, the longest stretch of perfectly homologous base sequence will normally primarily determine hybrid stability.

Amplification primers and probes should be positioned to minimize the stability of the oligonucleotide:nontarget (i.e., nucleic acid with similar sequence to target nucleic acid) nucleic acid hybrid. It is preferred that the amplification primers and detection probes are able to distinguish between target and non-target sequences. In designing primers and probes, the differences in these  $T_m$  values should be as large as possible (e.g., at least 2°C and preferably 5°C.).

The degree of non-specific extension (primer-dimer or non-target copying) can also affect amplification efficiency. For this reason, primers are selected to have low self- or cross-complementarity, particularly at the 3' ends of the sequence. Long homopolymer tracts and high GC content are avoided to reduce spurious primer extension. Commercially available computer software can aid in this aspect of the design. Available computer programs include MacDNASIS™ 2.0 (Hitachi Software Engineering American Ltd.) and OLIGO ver. 6.6 (Molecular Biology Insights; Cascade, CO).

Those having an ordinary level of skill in the art will appreciate that hybridization involves the association of two single strands of complementary nucleic acid to form a hydrogen bonded double strand. It is implicit that if one of the two strands is wholly or partially involved in a hybrid, then that strand will be less able to participate in formation of a new hybrid. By designing primers and probes so that substantial portions of the sequences of interest are single stranded, the rate and extent of hybridization may be greatly increased. If the target is an integrated genomic sequence, then it will naturally occur in a double stranded form (as is the case with the product of the polymerase chain reaction). These double-stranded targets are naturally inhibitory to hybridization with a probe and require denaturation prior to the hybridization step.

The rate at which a polynucleotide hybridizes to its target is a measure of the thermal stability of the target secondary structure in the target binding region. The standard

WO 2004/036190-meas WO 2004/036190-ization rate is the  $C_0t_{1/2}$  which is measured as moles per liter multiplied by seconds. Thus, it is the concentration of probe multiplied by the time at which 50% of maximal hybridization occurs at that concentration. This value is determined by hybridizing various amounts of polynucleotide to a constant amount of target for a fixed time. The  $C_0t_{1/2}$  is found graphically by standard procedures familiar to those having an ordinary level of skill in the art.

#### Preferred Amplification Primers

Primers useful for conducting amplification reactions can have different lengths to accommodate the presence of extraneous sequences that do not participate in target binding, and that may not substantially affect amplification or detection procedures. For example, promoter-primers useful for performing amplification reactions in accordance with the invention have at least a minimal sequence that hybridizes to the WNV target nucleic acid, and a promoter sequence positioned upstream of that minimal sequence. However, insertion of sequences between the target binding sequence and the promoter sequence could change the length of the primer without compromising its utility in the amplification reaction. Additionally, the lengths of the amplification primers and detection probes are matters of choice as long as the sequences of these oligonucleotides conform to the minimal essential requirements for hybridizing the desired complementary sequence.

Tables 1 and 2 present specific examples of oligonucleotide sequences that were used as primers for amplifying WNV nucleic acids in the 5' non-coding region. Table 1 presents the sequences of primers that were complementary to WNV sequences on one strand of nucleic acid. All of the illustrative primers presented in Table 1 have target-complementary sequences contained within the sequence of SEQ ID NO:1. Different subsets of preferred primers have target-complementary sequences contained within the sequence of SEQ ID NO:2 or SEQ ID NO:3. It is preferred for one of the primers used in the amplification procedure to have a target-complementary sequence falling within one of these domains. Table 2 presents the sequences of both the WNV target-complementary primers and the full sequences for promoter-primers that were used during development of the invention. All of the illustrative primers presented in Table 2 have target-complementary sequences contained within the sequence of SEQ ID NO:16, a feature which is presently preferred for one of the primers used in the amplification procedure. Notably, the oligonucleotide sequences in Table 1 and Table 2 are complementary to opposite strands of the WNV nucleic acid.

Primers useful for amplifying the 5' non-coding region of WNV can include nucleotide analogs. For example, the primers of SEQ ID NO:4 and SEQ ID NO:5 differ from each other by the substitution of a hypoxanthine base analog for an adenine base at position 11. Similarly, the primers of SEQ ID NO:6 and SEQ ID NO:7 also differ by the presence of this base analog, as do the opposite strand primers identified by SEQ ID NO:21 and SEQ ID NO:22. This illustrates how nucleobases in the primers may be substituted by modified bases or nucleobase analogs.

Table 1

Polynucleotide Sequences of Amplification Primers

Sequence	SEQ ID NO:
CAATTAACACAGTGCGAGCTGTTT	SEQ ID NO:4
CAATTAACACIGTGCGAGCTGTTT	SEQ ID NO:5
TAACACAGTGCGAGCTGTTTCTT	SEQ ID NO:6
TAACACIGTGCGAGCTGTTTCTT	SEQ ID NO:7
CGAGCTGTTTCTTAGCACGA	SEQ ID NO:8
CGAGCTGTTTCTTAGCACGAA	SEQ ID NO:9
GAAGATCTCGATGTCTAAGAAACC	SEQ ID NO:10
AAGATCTCGATGTCTAAGAAACC	SEQ ID NO:11
AGATCTCGATGTCTAAGAAACC	SEQ ID NO:12
GATCTCGATGTCTAAGAAACCA	SEQ ID NO:13
GATCTCGATGTCTAAGAAACC	SEQ ID NO:14
ATCTCGATGTCTAAGAAACCAG	SEQ ID NO:15

Table 2 presents WNV target-complementary oligonucleotide sequences and the corresponding promoter-primer sequences that were used for amplifying WNV nucleic acid sequences in the 5' non-coding region of the viral genome. As indicated above, all promoter-primers included sequences complementary to a WNV target sequence at their 3' ends, and a T7 promoter sequence at their 5' ends. Primers identified by SEQ ID Nos:29-40 in Table 2 are promoter-primers corresponding to the WNV-complementary primers identified as SEQ ID Nos:17-28, respectively.

Table 2

## Polynucleotide Sequences of Amplification Primers

	Sequence	SEQ ID NO:
	GTTTTAGCATATTGACAGCCC	SEQ ID NO:17
5	GTTTTAGCATATTGACAGCC	SEQ ID NO:18
	TTCCGCGTTTTAGCATATTGA	SEQ ID NO:19
	ATTCCGCGTTTTAGCATATTG	SEQ ID NO:20
	ATCAAGGACAACACGCGGGGCAT	SEQ ID NO:21
	ATCAAGGACAACACGCGGGGCAT	SEQ ID NO:22
10	CCTCTTCAGTCCAATCAAGGACAA	SEQ ID NO:23
	AGCCCTCTTCAGTCCAATCAAGGA	SEQ ID NO:24
	TAGCCCTCTTCAGTCCAATCAAGG	SEQ ID NO:25
	ATAGCCCTCTTCAGTCCAATCAAG	SEQ ID NO:26
	TAGCCCTCTTCAGTCCAATCAA	SEQ ID NO:27
15	ACATAGCCCTCTTCAGTCCAATCA	SEQ ID NO:28
	AATTTAATACGACTCACTATAGGGAGAGTTTTAGCATATTGACAGCCC	SEQ ID NO:29
	AATTTAATACGACTCACTATAGGGAGAGTTTTAGCATATTGACAGCC	SEQ ID NO:30
	AATTTAATACGACTCACTATAGGGAGATTCCGCGTTTTAGCATATTGA	SEQ ID NO:31
	AATTTAATACGACTCACTATAGGGAGAATTCCGCGTTTTAGCATATTG	SEQ ID NO:32
20	AATTTAATACGACTCACTATAGGGAGAATCAAGGACAACACGCGGGGC AT	SEQ ID NO:33
	AATTTAATACGACTCACTATAGGGAGAATCAAGGACAACACGCGGGGC AT	SEQ ID NO:34
25	AATTTAATACGACTCACTATAGGGAGACCTCTTCAGTCCAATCAAGGA CAA	SEQ ID NO:35
	AATTTAATACGACTCACTATAGGGAGAAGCCCTCTTCAGTCCAATCAA GGA	SEQ ID NO:36
	AATTTAATACGACTCACTATAGGGAGATAGCCCTCTTCAGTCCAATCAA GG	SEQ ID NO:37
30	AATTTAATACGACTCACTATAGGGAGAATAGCCCTCTTCAGTCCAATCA AG	SEQ ID NO:38
	AATTTAATACGACTCACTATAGGGAGATAGCCCTCTTCAGTCCAATCAA	SEQ ID NO:39
35	AATTTAATACGACTCACTATAGGGAGAACATAGCCCTCTTCAGTCCAAT CA	SEQ ID NO:40

include a first primer that hybridizes a WNV target sequence (such as one of the primers listed in Table 2) and a second primer that is complementary to the sequence of an extension product of the first primer (such as one of the primer sequences listed in Table 1). In a highly preferred embodiment, the first primer is a promoter-primer that includes a T7 promoter sequence at its 5' end.

Tables 3 and 4 present specific examples of oligonucleotide sequences that were used as primers for amplifying WNV nucleic acids in the 3000 region of the viral genome. Table 3 presents the sequences of primers that were complementary to WNV sequences on one strand of nucleic acid. All of the illustrative primers presented in Table 3 have target-complementary sequences contained within the sequence of SEQ ID NO:41, a feature which is presently preferred for one of the primers used in the amplification procedure. Table 4 presents the sequences of both the WNV target-complementary primers and the full sequences for promoter-primers that were used during development of the invention. All of the illustrative primers presented in Table 4 have target-complementary sequences contained within the sequence of SEQ ID NO:52, a feature which is presently preferred for one of the primers used in the amplification procedure. Notably, the oligonucleotide sequences in Table 3 and Table 4 are complementary to opposite strands of the WNV nucleic acid.

Primers useful for amplifying the 3000 region of WNV can include nucleotide analogs. For example, the primers of SEQ ID NO:42, SEQ ID NO:47 and SEQ ID NO:48 differ from each other by the substitution of a hypoxanthine base analog for the existing base at different individual positions within the primer sequence. Similarly, the primers of SEQ ID NO:43 and SEQ ID NO:49 also differ by the presence of this base analog, as do the primers identified by SEQ ID NO:45 and SEQ ID NO:50 and SEQ ID NO:51. This illustrates that nucleobases in the primers may be substituted by modified bases or nucleobase analogs.

Polynucleotide Sequences of Amplification Primers

Sequence	SEQ ID NO:
TTGACCCCTTTTCAGTTGGGCCTT	SEQ ID NO:42
CTTTTCAGTTGGGCCTTCTGGT	SEQ ID NO:43
AGTTGGGCCTTCTGGTCGTGTT	SEQ ID NO:44
TGGTCGTGTTCTTGGCCACCCA	SEQ ID NO:45
TCGTGTTCTTGGCCACCCAGGA	SEQ ID NO:46
TTGAICCTTTTCAGTTGGGCCTT	SEQ ID NO:47
TTGACCCCTTTTCAGTTGGGCCTT	SEQ ID NO:48
CTTTTCAGTTGGGCCTTCTGGT	SEQ ID NO:49
TGGTCGTGTTTGGCCACCCA	SEQ ID NO:50
TGGTCGTGTTCTTGGCCACCCA	SEQ ID NO:51

Table 4 presents WNV target-complementary oligonucleotide sequences and the corresponding promoter-primer sequences that were used for amplifying WNV nucleic acid sequences in the 3000 region of the viral genome. As indicated above, all promoter-primers included sequences complementary to a WNV target sequence at their 3' ends, and a T7 promoter sequence at their 5' ends.



Table 4

Polynucleotide Sequences of Amplification Primers

Identifier	Sequence	SEQ ID NO:
WNV complementary primer	CTGGCATGCTGATCTTGGCTGT	SEQ ID NO:53
WNV complementary primer	ATAGCTGGCATGCTGATCTTGGC	SEQ ID NO:54
WNV complementary primer	ATAGCTGGCATGCTGATCTTGG	SEQ ID NO:55
T7 promoter-primer	AATTTAATACGACTCACTATAGGGA GACTGGCATGCTGATCTTGGCTGT	SEQ ID NO:56
T7 promoter-primer	AATTTAATACGACTCACTATAGGGA GAATAGCTGGCATGCTGATCTTGGC	SEQ ID NO:57
T7 promoter-primer	AATTTAATACGACTCACTATAGGGA GAATAGCTGGCATGCTGATCTTGG	SEQ ID NO:58

Preferred sets of primers for amplifying WNV sequences in the 3000 region of the viral genome include a first primer that hybridizes a WNV target sequence (such as one of the primers listed in Table 4) and a second primer that is complementary to the sequence of an extension product of the first primer (such as one of the primer sequences listed in Table 3). In a highly preferred embodiment, the first primer is a promoter-primer that includes a T7 promoter sequence at its 5' end.

Tables 5 and 6 present specific examples of oligonucleotide sequences that were used as primers for amplifying WNV nucleic acids in the 3' non-coding region of the viral genome. Table 5 presents the sequences of primers that were complementary to WNV sequences on one strand of nucleic acid. All of the illustrative primers presented in Table 5 have target-complementary sequences contained within the sequence of SEQ ID NO:59, a feature which is presently preferred for one of the primers used in the amplification procedure. Table 6 presents the sequences of both the WNV target-complementary primers and the full sequences for promoter-primers that were used during development of the invention. All of the illustrative primers presented in Table 6 have target-complementary sequences contained within the sequence of SEQ ID NO:72. Different subsets of preferred primers have target-complementary sequences contained within the sequence of SEQ ID NO:73 or SEQ ID NO:74. It is preferred for one of the primers used in the amplification procedure to have a target-complementary sequence falling within one of these domains. Notably, the oligonucleotide sequences in Table

5 and Table 6 are complementary to opposite strands of the WNV nucleic acid.

Primers useful for amplifying the 3' non-coding region of WNV can include nucleotide analogs. For example, the primers of SEQ ID NO:60 and SEQ ID NO:61 differ from each other by the substitution of a hypoxanthine base analog for a thymine base at position 1.

Similarly, the primers of SEQ ID NO:64 and SEQ ID NO:65 also differ by the presence of this base analog, in this instance substituting for cytosine. Likewise, the WNV-complementary primer sequences of SEQ ID NO:83 and SEQ ID NO:82, together with the corresponding promoter-primer sequences, also contain hypoxanthine base analog substitutions. This further illustrates that nucleobases in the primers may be substituted by modified bases or nucleobase analogs.

**Table 5**

Polynucleotide Sequences of Amplification Primers

Sequence	SEQ ID NO:
TCCGCCACCGGAAGTTGAG	SEQ ID NO:60
ICCGCCACCGGAAGTTGAG	SEQ ID NO:61
TCCGCCACCGGAAGTTGAGT	SEQ ID NO:62
TCCGCCACCGGAAGTTGAGTA	SEQ ID NO:63
CGCCACCGGAAGTTGAGT	SEQ ID NO:64
IGCCACCGGAAGTTGAGT	SEQ ID NO:65
CGCCACCGGAAGTTGAGTA	SEQ ID NO:66
GGAAGTTGAGTAGACGGTGCT	SEQ ID NO:67
GGAAGTTGAGTAGACGGTGCTG	SEQ ID NO:68
GAAGTTGAGTAGACGGTGCT	SEQ ID NO:69
GAAGTTGAGTAGACGGTGCTG	SEQ ID NO:70
AAGTTGAGTAGACGGTGCTG	SEQ ID NO:71

Table 6 presents WNV target-complementary oligonucleotide sequences and the corresponding promoter-primer sequences that were used for amplifying WNV nucleic acid sequences in the 3' non-coding region of the viral genome. As indicated above, all promoter-primers included sequences complementary to a WNV target sequence at their 3' ends, and a T7 promoter sequence at their 5' ends.

Table 6

Polynucleotide Sequences of Amplification Primers

	Sequence	SEQ ID NO:
	TCCGAGACGGTTCTGAGGGCTTAC	SEQ ID NO:75
5	TCCGAGACGGTTCTGAGGGCTTA	SEQ ID NO:76
	TCCGAGACGGTTCTGAGGGCTT	SEQ ID NO:77
	CCAGTCCTCCTGGGGTTGAG	SEQ ID NO:78
	ACCCAGTCCTCCTGGGGTTGAG	SEQ ID NO:79
	ACCCAGTCCTCCTGGGGTTGA	SEQ ID NO:80
0	ACCCAGTCCTCCTGGGGTTG	SEQ ID NO:81
	GCTACAICAIGTGGGGTCCT	SEQ ID NO:82
	GCTACAACAIGTGGGGTCCT	SEQ ID NO:83
	AATTTAATACGACTCACTATAGGGAGATCCGAGACGGTTCTGAGGGCT TAC	SEQ ID NO:84
5	AATTTAATACGACTCACTATAGGGAGATCCGAGACGGTTCTGAGGGCT TA	SEQ ID NO:85
	AATTTAATACGACTCACTATAGGGAGATCCGAGACGGTTCTGAGGGCT T	SEQ ID NO:86
	AATTTAATACGACTCACTATAGGGAGACCCAGTCCTCCTGGGGTTGAG	SEQ ID NO:87
20	AATTTAATACGACTCACTATAGGGAGAACCCAGTCCTCCTGGGGTTGA G	SEQ ID NO:88
	AATTTAATACGACTCACTATAGGGAGAACCCAGTCCTCCTGGGGTTGA	SEQ ID NO:89
	AATTTAATACGACTCACTATAGGGAGAACCCAGTCCTCCTGGGGTTG	SEQ ID NO:90
	AATTTAATACGACTCACTATAGGGAGAGCTACAICAIGTGGGGTCCT	SEQ ID NO:91
25	AATTTAATACGACTCACTATAGGGAGAGCTACAACAIGTGGGGTCCT	SEQ ID NO:92

Preferred sets of primers for amplifying WNV sequences in the 3' non-coding region include a first primer that hybridizes a WNV target sequence (such as one of the primers listed in Table 6) and a second primer that is complementary to the sequence of an extension product of the first primer (such as one of the primer sequences listed in Table 5). In a highly preferred embodiment, the first primer is a promoter-primer that includes a T7 promoter sequence at its 5' end. Primers identified by SEQ ID Nos:84-92 in Table 6 are promoter-primers

WO 2004/036190 PCT/US2003/033639  
corresponding to the WNV-complementary primers identified as SEQ ID Nos: 75-83,  
respectively.

#### Preferred Detection Probes

Another aspect of the invention relates to oligonucleotides that can be used as  
5 hybridization probes for detecting WNV nucleic acids. Methods for amplifying a target nucleic  
acid sequence present in the nucleic acid of WNV can include an optional further step for  
detecting amplicons. This procedure for detecting WNV nucleic acids includes a step for  
contacting a test sample with a hybridization assay probe that preferentially hybridizes to the  
10 target nucleic acid sequence, or the complement thereof, under stringent hybridization  
conditions, thereby forming a probe:target duplex that is stable for detection. Next there is a  
step for determining whether the hybrid is present in the test sample as an indication of the  
presence or absence of WNV nucleic acids in the test sample. This may involve detecting the  
probe:target duplex, and preferably involve homogeneous assay systems.

Hybridization assay probes useful for detecting WNV nucleic acid sequences include a  
15 sequence of bases substantially complementary to a WNV target nucleic acid sequence. Thus,  
probes of the invention hybridize one strand of a WNV target nucleic acid sequence, or the  
complement thereof. These probes may optionally have additional bases outside of the targeted  
nucleic acid region which may or may not be complementary to WNV nucleic acid.

Preferred probes are sufficiently homologous to the target nucleic acid to hybridize  
20 under stringent hybridization conditions corresponding to about 60°C when the salt  
concentration is in the range of 0.6-0.9 M. Preferred salts include lithium chloride, but other  
salts such as sodium chloride and sodium citrate also can be used in the hybridization solution.  
Example high stringency hybridization conditions are alternatively provided by 0.48 M sodium  
phosphate buffer, 0.1% sodium dodecyl sulfate, and 1 mM each of EDTA and EGTA, or by 0.6  
25 M LiCl, 1% lithium lauryl sulfate, 60 mM lithium succinate and 10 mM each of EDTA and  
EGTA.

Probes in accordance with the invention have sequences complementary to, or  
corresponding to one of three different domains of the WNV genome. As reiterated below,  
these domains were: (1) the 5' non-coding region/capsid region, (2) the 3000 region, and (3)  
30 the 3' non-coding region. Certain probes that are preferred for detecting WNV nucleic acid  
sequences have a probe sequence, which includes the target-complementary sequence of bases  
together with any base sequences that are not complementary to the nucleic acid that is to be

WO 2004/036190 PCT/US2003/033639  
detected, in the length range of from 10-100 nucleotides. Certain specific probes are preferred for detecting WNV nucleic acid sequences have target-complementary sequences in the length range of from 12-87, from 10-20, from 13-37 or from 17-23 nucleotides. Of course, these target-complementary sequences may be linear sequences, or may be contained in the structure of a molecular beacon or other construct having one or more optional nucleic acid sequences that are non-complementary to the WNV target sequence that is to be detected. As indicated above, probes may be made of DNA, RNA, a combination DNA and RNA, a nucleic acid analog, or contain one or more modified nucleosides (e.g., a ribonucleoside having a 2'-O-methyl substitution to the ribofuranosyl moiety).

Simply stated, preferred probes for detecting target nucleic acids of interest in connection with the present invention include sequences that are contained within one or more of several defined probe domains or the complements thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs, up to 10% mismatched bases, and even up to 20% mismatched bases. For example, preferred hybridization assay probes for detecting flaviviral nucleic acids, such as the nucleic acids of WNV, in the 5' non-coding region can include target-complementary sequences of bases contained within the sequence of SEQ ID NO:93, or within one of the subdomains defined by SEQ ID NO:94 or SEQ ID NO:95. Preferred hybridization assay probes for detecting flaviviral nucleic acids, such as the nucleic acids of WNV, in the 3000 region include target-complementary sequences of bases contained within the sequence of SEQ ID NO:99. Preferred hybridization assay probes useful for detecting flaviviral nucleic acids, such as the nucleic acids of WNV, in the 3' non-coding region include target-complementary sequences of bases contained within the sequence of SEQ ID NO:101, or within the subdomains defined by SEQ ID NO:102 or SEQ ID NO:103. Optional sequences which are not complementary to the nucleic acid sequence that is to be detected may be linked to the target-complementary sequence of the probe.

Referring particularly to the allowability of base differences which can distinguish useful probe sequences from a defined target region which contains the target-complementary complementary sequence of bases of that probe, it should be noted that base position 12 of the probe having the sequence of SEQ ID NO:114 (occupied by a T) differs from the corresponding position in the domain sequences defined by SEQ ID NO:101, SEQ ID NO:102 and SEQ ID NO:103 (all of which have a C at the corresponding position).

Certain preferred probes in accordance with the present invention include a detectable

WO 2004/036190 PCT/US2003/033639  
label. In one embodiment this label is an acridinium ester joined to the probe by means of a  
non-nucleotide linker. For example, detection probes can be labeled with chemiluminescent  
acridinium ester compounds that are attached via a linker substantially as described in U.S.  
Patent No. 5,585,481; and in U.S. Patent No. 5,639,604, particularly as described at column 10,  
5 line 6 to column 11, line 3, and in Example 8. The disclosures contained in these patent  
documents are hereby incorporated by reference.

Table 7 presents the base sequences of some of the hybridization probes that were used  
for detecting WNV amplicons from each of the three WNV target regions. Since alternative  
probes for detecting WNV nucleic acid sequences can hybridize to the opposite-sense strand of  
10 WNV, the present invention also includes oligonucleotides that are complementary to the  
sequences presented in the table.

## Polynucleotide Sequences of WNV Detection Probes

Target	Sequence	SEQ ID NO:
5' Non-Coding Region	TGTCTAAGAAACCAGGAGGGC	SEQ ID NO:96
	GAAACCAGGAGGGCCCGG	SEQ ID NO:97
	GCTGTCAATATGCTAAAACG	SEQ ID NO:98
3000 Region	GGTCCTTCGCAAGAGGTGG	SEQ ID NO:100
3' Non-Coding Region	GAGTAGACGGTGCTGCCTGCG	SEQ ID NO:104
	GTAGACGGTGCTGCCTGCG	SEQ ID NO:105
	TGCGACTCAACCCCAGGAGGAC	SEQ ID NO:106
	TGCGACTCAACCCCAGGA	SEQ ID NO:107
	CGACTCAACCCCAGGAGGAC	SEQ ID NO:108
	GACTCAACCCCAGGAGGAC	SEQ ID NO:109
	GACTCAACCCCAGGAGGA	SEQ ID NO:110
	ACTCAACCCCAGGAGGAC	SEQ ID NO:111
	CAGGAGGACUGGGUGAACA	SEQ ID NO:112
	GAGGACUGGGUGAACAAAG	SEQ ID NO:113
	GTGAACAAAGCTGCGAAGTG	SEQ ID NO:114
	AAGCCGCGAAGTGATCCATG	SEQ ID NO:115
	GTAAGCCCTCAGAACCGTC	SEQ ID NO:116

As indicated above, any number of different backbone structures can be used as a scaffold for the nucleobase sequences of the invented hybridization probes. In certain highly preferred embodiments, the probe sequence used for detecting WNV amplicons includes a methoxy backbone, or at least one methoxy linkage in the nucleic acid backbone.

Selection and Use of Capture Oligonucleotides

Preferred capture oligonucleotides include a first sequence that is complementary to a WNV sequence (i.e., a "WNV target sequence") covalently attached to a second sequence (i.e., a "tail" sequence) that serves as a target for immobilization on a solid support. Any backbone to link the base sequence of a capture oligonucleotide may be used. In certain preferred  
5 embodiments the capture oligonucleotide includes at least one methoxy linkage in the backbone. The tail sequence, which is preferably at the 3' end of a capture oligonucleotide, is used to hybridize to a complementary base sequence to provide a means for capturing the hybridized target WNV nucleic acid in preference to other components in the biological  
0 sample.

Although any base sequence that hybridizes to a complementary base sequence may be used in the tail sequence, it is preferred that the hybridizing sequence span a length of about 5-50 nucleotide residues. Particularly preferred tail sequences are substantially homopolymeric, containing about 10 to about 40 nucleotide residues, or more preferably about 14 to about 30  
5 residues. A capture oligonucleotide according to the present invention may include a first sequence that specifically binds a WNV target polynucleotide, and a second sequence that specifically binds an oligo(dT) stretch immobilized to a solid support.

Using the components illustrated in Figure 1, one assay for detecting WNV sequences in a biological sample includes the steps of capturing the target nucleic acid using the capture  
20 oligonucleotide, amplifying the captured target region using at least two primers, and detecting the amplified nucleic acid by first hybridizing the labeled probe to a sequence contained in the amplified nucleic acid and then detecting a signal resulting from the bound labeled probe.

The capturing step preferably uses a capture oligonucleotide where, under hybridizing conditions, one portion of the capture oligonucleotide specifically hybridizes to a sequence in  
25 the target nucleic acid and a tail portion serves as one component of a binding pair, such as a ligand (e.g., a biotin-avidin binding pair) that allows the target region to be separated from other components of the sample. Preferably, the tail portion of the capture oligonucleotide is a sequence that hybridizes to a complementary sequence immobilized to a solid support particle. Preferably, first, the capture oligonucleotide and the target nucleic acid are in solution to take  
30 advantage of solution phase hybridization kinetics. Hybridization produces a capture oligonucleotide:target nucleic acid complex which can bind an immobilized probe through hybridization of the tail portion of the capture oligonucleotide with a complementary



oligonucleotide and immobilized probe is formed under hybridization conditions. Preferably, the immobilized probe is a repetitious sequence, and more preferably a homopolymeric sequence (e.g., poly-A, poly-T, poly-C or poly-G), which is complementary to the tail sequence and attached to a solid support. For example, if the tail portion of the capture oligonucleotide contains a poly-A sequence, then the immobilized probe would contain a poly-T sequence, although any combination of complementary sequences may be used. The capture oligonucleotide may also contain "spacer" residues, which are one or more bases located between the base sequence that hybridizes to the target and the base sequence of the tail that hybridizes to the immobilized probe. Any solid support may be used for binding the target nucleic acid:capture oligonucleotide complex. Useful supports may be either matrices or particles free in solution (e.g., nitrocellulose, nylon, glass, polyacrylate, mixed polymers, polystyrene, silane polypropylene and, preferably, magnetically attractable particles). Methods of attaching an immobilized probe to the solid support are well known. The support is preferably a particle which can be retrieved from solution using standard methods (e.g., centrifugation, magnetic attraction of magnetic particles, and the like). Preferred supports are paramagnetic monodisperse particles (i.e., uniform in size  $\pm$  about 5%).

Retrieving the target nucleic acid:capture oligonucleotide:immobilized probe complex effectively concentrates the target nucleic acid (relative to its concentration in the biological sample) and purifies the target nucleic acid from amplification inhibitors which may be present in the biological sample. The captured target nucleic acid may be washed one or more times, further purifying the target, for example, by resuspending the particles with the attached target nucleic acid:capture oligonucleotide:immobilized probe complex in a washing solution and then retrieving the particles with the attached complex from the washing solution as described above. In a preferred embodiment, the capturing step takes place by sequentially hybridizing the capture oligonucleotide with the target nucleic acid and then adjusting the hybridization conditions to allow hybridization of the tail portion of the capture oligonucleotide with an immobilized complementary sequence (e.g., as described in PCT No. WO 98/50583). After the capturing step and any optional washing steps have been completed, the target nucleic acid can then be amplified. To limit the number of handling steps, the target nucleic acid optionally can be amplified without releasing it from the capture oligonucleotide.

Useful capture oligonucleotides may contain mismatches to the above-indicated

sequences, as long as the mismatched sequences hybridize to the WNV nucleic acid containing the sequence that is to be amplified. Each capture oligonucleotide described herein included one of the WNV-complementary sequences presented in Table 8 linked to a poly-(dA) tail at its 3' end. All of the capture oligonucleotides also included three optional thymidine nucleotides interposed between the WNV-complementary sequence and the poly-(dA) tail. The presence of these thymidine nucleotides is not believed to be essential for success of the capture procedure. The three thymidine nucleotides and the poly-(dA) tail were synthesized using DNA precursors, while the WNV-complementary portions of the oligonucleotides were synthesized using 2'-OMe nucleotide analogs.

WNV-Complementary Portions of Capture Oligonucleotides

Sequence	SEQ ID NO:
AAUCCUCACAAACACUACUAAGU	SEQ ID NO:117
AAGAACGCCAAGAGAGCCAACAC	SEQ ID NO:118
CCUCUUUUUCUUUUGUUUUGAGCUCCG	SEQ ID NO:119
AATCCTCACAAACACTACTAAGT	SEQ ID NO:120
CCTCCTCTTTTCTTTTGTTTTG	SEQ ID NO:121
CCUCCUCUUUUCUUUUGUUUUGAGC	SEQ ID NO:122
CCTCCTCTTTTCTTTTGTTTTGAGC	SEQ ID NO:123
UUCAUCGCUGUUUGUUUGUUCAC	SEQ ID NO:124
TGTGTCTGCACTGTCAGTGACCT	SEQ ID NO:125
UGUGUCUGCACUGUCAGUGACCU	SEQ ID NO:126
GUUUUGUCUCCAUCCAUUCA	SEQ ID NO:127
GUUUUGUCUCCAUCCAUUCAU	SEQ ID NO:128
UCUCUCUCUUUCCCAUCAUGUUGUA	SEQ ID NO:129
CCUCCUCUUUUCUUUUGUUUUG	SEQ ID NO:130
CCAACUGAUCCAAAGUCCCAAGC	SEQ ID NO:131
ACCCCUCCAACUGAUCCAAAGUCC	SEQ ID NO:132
GAACACCCCUCCAACUGAUCCAAA	SEQ ID NO:133
GCAGGUCCACGGUGUCCGCA	SEQ ID NO:134
UUCAUCGCUGUUUGUUUGUUCAC	SEQ ID NO:135
CCTCCTCTTTTCTTTTGTTTTG	SEQ ID NO:136
GCAGGTCCACGGTGTCCGCA	SEQ ID NO:137
CUCCAUCCAUUCUUCUCCUC	SEQ ID NO:138
GUUUUGUCUCCAUCCAUUCUUC	SEQ ID NO:139
GTTTTGTCTTCCATCCATTCAT	SEQ ID NO:140
CTGGGGTTTTGTCTTCCATCCAT	SEQ ID NO:141
CUGGGGUUUUGUCUCCAUCCAU	SEQ ID NO:142

Preferred Methods for Amplifying and Detecting WNV Polynucleotide Sequences

Preferred methods of the present invention are described and illustrated by the Examples presented below. Figure 1 schematically illustrates one system that may be used for detecting a target region of the WNV genome (shown by a thick solid horizontal line). This system includes four oligonucleotides (shown by the shorter solid lines): one capture oligonucleotide that includes a sequence that hybridizes specifically to a WNV sequence in the target region and a tail ("T") that hybridizes to a complementary sequence immobilized on a solid support to capture the target region present in a biological sample; one T7 promoter-primer which includes a sequence that hybridizes specifically to a WNV sequence in the target region and a T7 promoter sequence ("P") which, when double-stranded, serves as a functional promoter for T7 RNA polymerase; one non-T7 primer which includes a sequence that hybridizes specifically to a first strand cDNA made from the target region sequence using the T7 promoter-primer; and one labeled probe which includes a sequence that hybridizes specifically to a portion of the target region that is amplified using the two primers.

As indicated above, amplifying the captured target region using the two primers can be accomplished by any of a variety of known nucleic acid amplification reactions that will be familiar to those having an ordinary level of skill in the art. In a preferred embodiment, a transcription-associated amplification reaction, such as TMA, is employed. In such an embodiment, many strands of nucleic acid are produced from a single copy of target nucleic acid, thus permitting detection of the target by detecting probes that are bound to the amplified sequences. Preferably, transcription-associated amplification uses two types of primers (one being referred to as a promoter-primer because it contains a promoter sequence, labeled "P" in Figure 1, for an RNA polymerase) two enzymes (a reverse transcriptase and an RNA polymerase), and substrates (deoxyribonucleoside triphosphates, ribonucleoside triphosphates) with appropriate salts and buffers in solution to produce multiple RNA transcripts from a nucleic acid template.

Referring to Figure 1, during transcription-mediated amplification, the captured target nucleic acid is hybridized to a first primer shown as a T7 promoter-primer. Using reverse transcriptase, a complementary DNA strand is synthesized from the T7 promoter-primer using the target DNA as a template. A second primer, shown as a non-T7 primer, hybridizes to the newly synthesized DNA strand and is extended by the action of a reverse transcriptase to form a DNA duplex, thereby forming a double-stranded T7 promoter region. T7 RNA polymerase

WO 2004/036190. PCT/US2003/033639  
then generates multiple RNA transcripts by using this functional T7 promoter. The autocatalytic mechanism of TMA employs repetitive hybridization and polymerization steps following a cDNA synthesis step using the RNA transcripts as templates to produce additional transcripts, thereby amplifying target region-specific nucleic acid sequences.

5 The detecting step uses at least one detection probe that binds specifically to the amplified RNA transcripts or amplicons described above. Preferably, the detection probe is labeled with a label that can be detected using a homogeneous detection system. For example, the labeled probe can be labeled with an acridinium ester compound from which a chemiluminescent signal may be produced and detected, as described above. Alternatively, the  
0 labeled probe may comprise a fluorophore or fluorophore and quencher moieties. A molecular beacon is one embodiment of such a labeled probe that may be used in a homogeneous detection system.

#### Kits for Detecting WNV Nucleic Acids

15 The present invention also embraces kits for performing polynucleotide amplification reactions using viral nucleic acid templates. Certain preferred kits will contain a hybridization assay probe that includes a target-complementary sequence of bases, and optionally including primers or other ancillary oligonucleotides for amplifying the target that is to be detected. Other preferred kits will contain a pair of oligonucleotide primers that may be used for amplifying  
20 target nucleic acids in an *in vitro* amplification reaction. Exemplary kits include first and second amplification oligonucleotides that are complementary to opposite strands of a WNV nucleic acid sequence that is to be amplified. The kits may further contain one or more oligonucleotide detection probes. Still other kits in accordance with the invention may additionally include capture oligonucleotides for purifying WNV template nucleic acids away from other species prior to amplification.

25 The general principles of the present invention may be more fully appreciated by reference to the following non-limiting Examples.

Example 1 describes procedures that identified some of the hybridization probes which subsequently were used in assays for detecting WNV nucleic acids. More particularly, the following procedures identified probes that were capable of hybridizing to nucleic acids  
30 corresponding to one of three different WNV domains. These domains were: (1) the 5' non-coding region/capsid region (5' NC/C), (2) the 3000 region (NS1/NS2a region), and (3) the 3' non-coding region (3' NC). Six synthetic oligonucleotides served as targets for binding the

Example 1

Oligonucleotide Probes for Detecting WNV

Synthetic WNV target oligonucleotides having the sequences presented in Table 9 were prepared according to standard laboratory procedures using 2'-OMe nucleotide analogs to mimic an RNA structure. Probes for hybridizing these synthetic WNV targets had the sequences given in Table 7, and were also prepared using 2'-OMe nucleotide analogs.

Table 9

Synthetic Target Sequences

Target	Target Sequence	SEQ ID NO:
5' Non-Coding Region	GCCCUCCUGGUUUCUAGACAUC	SEQ ID NO:143
	UUGCCGGGCCCUCCUGGUUUCUAGACA UC	SEQ ID NO:144
	CGCGUUUAGCAUAUUGACAGCCC	SEQ ID NO:145
3000 Region	UCCACCUCUUGCGAAGGACCUC	SEQ ID NO:146
3' Non-Coding Region	GUCGCAGGCAGCACCGUCUACUCAAC	SEQ ID NO:147
	CAGUCCUCCUGGGGUUGAGUCGCA	SEQ ID NO:148
	GAGACGGUUCUGAGGGCUUACAU	SEQ ID NO:149
	CAGUCCCCCUGGGGUUGAGUCGCA	SEQ ID NO:150
	CAGUCCUCCUGGGGUUGAGCCGCA	SEQ ID NO:151
	CAGUCAUCCUGGGGUUGAGUCGCA	SEQ ID NO:152

Hybridization reactions included about  $1 \times 10^6$  RLUs of AE-labeled probe having a specific activity of about  $2 \times 10^8$  RLU/pmole, and about 0.5 pmoles of synthetic WNV target oligonucleotide. Negative control reactions omitted the WNV target oligonucleotide. The probes listed in Table 7 were each labeled with an AE moiety joined to the oligonucleotide structure by an internally disposed non-nucleotide linker according to procedures described in U.S. Patent Nos. 5,585,481 and 5,639,604, the disclosures of these patents having been

incorporated by reference hereinabove. The linker on the probe of SEQ ID NO:96 was

alternatively located between positions 5 and 6, between positions 9 and 10, between positions 13 and 14, or between positions 16 and 17. The linker on the probe of SEQ ID NO:97 was located between positions 9 and 10. The linker on the probe of SEQ ID NO:98 was

alternatively located between positions 6 and 7, between positions 9 and 10, or between positions 11 and 12. The linker on the probe of SEQ ID NO:100 was alternatively located between positions 6 and 7, between positions 9 and 10, between positions 11 and 12, or between positions 13 and 14. The linker on the probe of SEQ ID NO:105 was alternatively

located between positions 12 and 13, or between positions 13 and 14. The linker on the probe of SEQ ID NO:106 was located between positions 14 and 15. The linker on the probe of SEQ ID NO:107 was alternatively located between positions 6 and 7, or between positions 7 and 8. The linker on the probe of SEQ ID NO:108 was alternatively located between positions 6 and 7, or between positions 12 and 13. The linker on the probe of SEQ ID NO:109 was

alternatively located between positions 5 and 6, or between positions 11 and 12. The linker on

the probe of SEQ ID NO:110 was located between positions 11 and 12. The linker on the probe of SEQ ID NO:111 was alternatively located between positions 9 and 10, between positions 10 and 11, between positions 12 and 13, or between positions 13 and 14. The linker on the probe of SEQ ID NO:112 was alternatively located between positions 7 and 8, between

positions 8 and 9, between positions 10 and 11, or between positions 11 and 12. The linker on

the probe of SEQ ID NO:113 was alternatively located between positions 7 and 8, between

positions 8 and 9, or between positions 9 and 10. The linker on the probe of SEQ ID NO:114

was located between positions 6 and 7. The linker on the probe of SEQ ID NO:115 was

alternatively located between positions 12 and 13, between positions 13 and 14, or between

positions 15 and 16. The linker on the probe of SEQ ID NO:116 was alternatively located

between positions 5 and 6, between positions 10 and 11, or between positions 12 and 13. Use

of all of these different linker positions confirmed the versatility of this labeling technique.

Probe hybridizations were carried out at 62°C for 15 minutes in 50 µl volumes of a succinate-

buffered solution that included about 300 mM LiCl and about 0.75% (w/v) lithium lauryl

sulfate. Hybridization reactions were followed by addition of 63 µl of 0.15 M sodium

tetraborate (pH 8.5), and 1% TRITON X-100 (Union Carbide Corporation; Danbury, CT).

These mixtures were first incubated at 62°C for 10 minutes to inactivate the chemiluminescent

label joined to unhybridized probe, and cooled briefly to 4°C prior to reading the hybridization

WO 2004/036190 PCT/US2003/033639  
 signal. Chemiluminescence due to hybridized probe in each sample was assayed using a  
 LUMISTAR GALAXY luminescence microplate reader (BMG Labtechnologies Inc.; Durham,  
 NC) configured for automatic injection of 1 mM nitric acid and 0.1% (v/v) hydrogen peroxide,  
 followed by injection of a solution containing 1 N sodium hydroxide. Results for the  
 5 chemiluminescent reactions were measured in relative light units (RLU). Representative  
 results from this procedure are summarized in Table 10 for each of the three different target  
 regions. Numerical values shown in the table indicate the average signal/noise ratio (S/N Avg.)  
 calculated from either one or two trials, where each trial included four replicates.

**Table 10**  
Probe Hybridization Results

Target Region	Probe Identifier	Synthetic Target Identifier	S/N Avg.†
5' Non-Coding Region	SEQ ID NO:96	SEQ ID NO:143	814
		SEQ ID NO:144	590 (n=1)
	SEQ ID NO:97	SEQ ID NO:144	45
	SEQ ID NO:98	SEQ ID NO:145	504
3000 Region	SEQ ID NO:100	SEQ ID NO:146	1312
3' Non-Coding Region	SEQ ID NO:104	SEQ ID NO:147	426
	SEQ ID NO:105	SEQ ID NO:147	720
	SEQ ID NO:106	SEQ ID NO:148	108
	SEQ ID NO:108		99
	SEQ ID NO:109		79
	SEQ ID NO:110		88
	SEQ ID NO:111		103
	SEQ ID NO:116	SEQ ID NO:149	609

† Unless indicated, all values represent the average of two trials (n=2) of four replicates each.

The results presented in Table 10 showed that each probe tested in the procedure gave a strong hybridization signal following interaction with the WNV target sequence. Numerical



probes used in the procedure gave S/N values substantially greater than 10 when hybridized with at least one of the synthetic targets. Indeed, the positioning of any detectable label joined to any of the probes described herein can be varied and still fall within the scope of the invention. Each of the probes having one of the alternatively positioned labels particularly described above represents a preferred embodiment of the invented probe.

sequences represents a preferred embodiment of the invention, and falls within at least one of the extended probe domains defined herein.

non-nucleotide linkers, as described above. More particularly, a probe having the sequence of

CCCTGCGACTCAACCCC (SEQ ID NO:189), having its linker located between positions 11 and 12, was hybridized to a synthetic WNV target having the sequence of SEQ ID NO:193 and gave a signal/noise ratio of about 180. A probe having the sequence of CCTGCGACTCAACCCC (SEQ ID NO:190), having its linker located between positions 13 and 14, was hybridized to a synthetic WNV target having the sequence of SEQ ID NO:193 and gave a signal/noise ratio of about 160. A probe having the sequence of CCTGCGACTCAACCCC (SEQ ID NO:191), having its linker located between positions 11 and 12, was hybridized to a synthetic WNV target having the sequence of SEQ ID NO:193 and gave a signal/noise ratio of about 190. Probes having the sequence of AGGAGGACTGGGTGAACAA (SEQ ID NO:192), with labels alternatively located between positions 7 and 8 or positions 8 and 9, were hybridized to a synthetic WNV target having the sequence of GAUCACUUCGCAGCUUUGUUCACCCAGUCCUCCUGG (SEQ ID NO:195) and gave signal/noise ratios of about 200. Again, each of the foregoing probe sequences represents a preferred embodiment of the invention, and falls within at least one of the extended probe domains defined herein.

The allowability of mismatches between a WNV target sequence and a substantially complementary hybridization probe was illustrated using one of the above-described probes, and a collection of synthetic targets representing naturally occurring variant sequences. More specifically, samples containing the above-described AE-labeled probe of SEQ ID NO:111 were hybridized with synthetic target oligonucleotides containing substantially complementary portions of the viral sequences identified by GenBank accession numbers AF297856 (SEQ ID NO:150), AF260969 (SEQ ID NO:151) and AF297847 (SEQ ID NO:152). Each target was mismatched to the labeled hybridization probe at a different position, meaning that the probe and target were not complementary at the position of the mismatch. The standard target of SEQ ID NO:148 was fully complementary to the probe, and so was used as a positive control. The ability of the probe to hybridize each of the targets was assessed by the above-described procedure as a function of the input level of target.

As illustrated in Figure 2, the hybridization probe clearly detected the targets which were not fully complementary to the probe sequence. This stringent test proved that mismatches between the hybridization probe and its target could be tolerated without compromising the ability of the probe to detect the target. Indeed, probes of the invention allowably may contain up to 10%, and even up to 20% base mismatches to the target without

target-complementary sequence of bases included in the invented hybridization probes  
allowably can differ from the extended domain sequence from which it was derived at up to  
10%, or even up to 20% of the base positions. Thus, hybridization probes and primers that are  
5 useful for detecting WNV will have target-complementary sequences of bases having a  
specified length range, and allowably may contain RNA and DNA equivalents, nucleotide  
analogues, and up to about 10%, or even up to 20% base differences when compared with a  
specified sequence which otherwise contains the probe or primer sequence. For example, a  
hybridization probe useful for detecting one of the above-described variant flavivirus sequences  
0 can have a target-complementary sequence of bases consisting of 18 contiguous bases  
contained within the sequence of SEQ ID NO:103 or SEQ ID NO:111 or the complements  
thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogues and up to  
10% base differences, or even up to 20% base differences.

Hybridization assay probes having the sequences presented in Table 7 were  
15 subsequently used for demonstrating that a range of amplification primers and capture  
oligonucleotides could detect WNV nucleic acids in biological samples. Probes having these  
sequences or their complements, allowing for the presence of RNA and DNA equivalents and  
nucleotide analogue substitutions, each represent particularly preferred embodiments of the  
invention.

20 Primers useful in accordance with the invention also exhibit flexibility with respect to  
the presence of base mismatches to an otherwise complementary target. This is because the  
amplification mechanism of nucleic acid amplification requires only transient primer binding to  
produce a first amplicon that will contain an exact match for complementary primer binding in  
a subsequent amplification cycle. Accordingly, and similar to the allowability of base  
25 differences or mismatches in hybridization probe sequences, primers that are useful for  
amplifying the nucleic acid sequences of flaviviruses, such as WNV, will have a 3' terminal  
target-complementary sequence of bases within a specified length range, allowing for the  
presence of RNA and DNA equivalents, nucleotide analogues and up to 10% base differences, or  
even up to 20% base differences when compared with a specified sequence that otherwise  
30 contains the primer sequence.

Preferred primer combinations for amplifying WNV nucleic acids were identified in a  
series of procedures that employed WNV virions as the source of nucleic acid templates.

WO 2004/036190 PCT/US2003/033639  
Promoter-primers and opposite strand primers were screened in combination using the method described below. Although these procedures were particularly carried out using a Transcription Mediated Amplification (TMA) protocol, the primers disclosed herein may be used to produce amplicons by alternative *in vitro* nucleic acid amplification methods that will be familiar to those having an ordinary level of skill in the art.

Example 2 describes the methods that identified useful amplification primers for the West Nile virus 5' non-coding region.

## Example 2

### Identification of Amplification Primers

A viral lysate served as the source of WNV template sequences in amplification reactions that employed paired sets of primers. TMA reactions were carried out essentially as described by Kacian et al., in U.S. Patent No. 5,399,491, the disclosure of this U.S. patent having been incorporated by reference hereinabove. Each promoter-primer included a T7 promoter sequence AATTTAATACGACTCACTATAGGGAGA (SEQ ID NO:153) upstream of a WNV-complementary sequence. Amplification reactions were conducted for various primer combinations using either 5 µl or 1.4 µl of a 1:10,000 dilution of a viral lysate of the NY99 WNV strain as a source of the WNV template (each reaction contained less than 1 PFU viral equivalents), and 10 pmoles of each primer in 100 µl of reaction buffer. The viral lysate was obtained from the Centers for Disease Control, National Center for Infectious Disease, Division of Vector-Borne Infectious Disease, Fort Collins, CO. Nucleic acids underwent specimen processing and target capture prior to amplification essentially according to the procedures disclosed in published International Patent Application No. PCT/US2000/18685, except that the template was captured using WNV-specific oligonucleotides rather than HIV-specific oligonucleotides. Sets of capture oligonucleotides having the sequences of SEQ ID NO:117, SEQ ID NO:118 and SEQ ID NO:119 or the sequences of SEQ ID NO:120, SEQ ID NO:126 and SEQ ID NO:130 were used in combination, each at a level of 2-5 pmoles/reaction for trials conducted using 5 µl of viral lysate as the source of template nucleic acids. In a slight variation of this procedure, capture oligonucleotides having the sequences of SEQ ID NO:120, SEQ ID NO:118 and SEQ ID NO:119 were used in combination, each at a level of 2-5 pmoles/reaction for trials conducted using 1.4 µl of viral lysate as the source of template nucleic acids. Target nucleic acids and primers were heated to 60°C for 10 minutes and then cooled to 42°C to facilitate primer annealing. Moloney Murine Leukemia Virus (MMLV)

were then added to the mixtures. The final amplification reactions contained 50 mM Tris HCl (pH 8.2 to 8.5), 35 mM KCl, 4 mM GTP, 4 mM ATP, 4 mM UTP, 4 mM CTP, 1 mM dATP, 1 mM dTTP, 1 mM dCTP, 1 mM dGTP, 20 mM MgCl<sub>2</sub>, 20 mM N-Acetyl-L-Cysteine, and 5% (w/v) glycerol. After a one hour incubation at 42 °C, the entire 100 µl amplification reaction was subjected to a hybridization assay essentially as described in Example 1 using the probe of SEQ ID NO:98 (see Table 10). More particularly, the probe was labeled with acridinium ester to a specific activity of about  $2 \times 10^8$  RLU/pmol and then used in an amount equivalent to  $2 \times 10^6$  RLU for each hybridization reaction. Trials were conducted using replicates of 10. To be judged as a positive result, either the chemiluminescent signal indicating probe hybridization must have exceeded 50,000 RLU in an assay, or the signal-to-noise ratio (where background noise was measured in a negative amplification control reaction) must have been at least 10.

Tables 11 and 12 present results from amplification procedures that were respectively conducted using amounts of WNV templates contained in 5 µl and 1.4 µl of viral lysate and different combinations of amplification primers. Results in the last columns of the tables show the number of positive trials and the number of replicate trials used in the procedures.

Amplification of WNV Polynucleotide Sequences Using  
Various Primer Combinations

WNV-Complementary Sequence of the Promoter-Primer	Opposite Strand Primer	# Positive/ # Tested
SEQ ID NO:21	SEQ ID NO:4	2/10 †
	SEQ ID NO:5	10/10 †
	SEQ ID NO:6	0/10 †
	SEQ ID NO:7	8/10 †
	SEQ ID NO:8	0/10 †
	SEQ ID NO:9	0/10 †
	SEQ ID NO:13	4/10 †
	SEQ ID NO:14	10/10 †
	SEQ ID NO:10	3/10 ‡
	SEQ ID NO:11	1/10 ‡
	SEQ ID NO:12	0/10 ‡
	SEQ ID NO:15	0/10 ‡
SEQ ID NO:22	SEQ ID NO:4	0/10 ‡
	SEQ ID NO:5	0/10 ‡
	SEQ ID NO:6	1/10 ‡
	SEQ ID NO:7	0/10 ‡
	SEQ ID NO:8	0/10 ‡
	SEQ ID NO:9	0/10 ‡
	SEQ ID NO:13	0/10 †
	SEQ ID NO:14	0/10 †
	SEQ ID NO:10	0/10 ‡
	SEQ ID NO:11	0/10 ‡
	SEQ ID NO:12	1/10 ‡
	SEQ ID NO:15	0/10 ‡
SEQ ID NO:23	SEQ ID NO:4	1/10 †
	SEQ ID NO:5	10/10 †
	SEQ ID NO:6	0/10 †
	SEQ ID NO:7	10/10 †
	SEQ ID NO:8	0/10 †
	SEQ ID NO:9	0/10 †
	SEQ ID NO:13	10/10 †
	SEQ ID NO:14	10/10 †
	SEQ ID NO:10	10/10 ‡
	SEQ ID NO:11	10/10 ‡
	SEQ ID NO:12	10/10 ‡
	SEQ ID NO:15	9/10 ‡

WNV-Complementary Sequence of the Promoter-Primer	Opposite Strand Primer	# Positive/ # Tested
SEQ ID NO:27	SEQ ID NO:4	2/10 †
	SEQ ID NO:5	0/10 †
	SEQ ID NO:6	0/10 †
	SEQ ID NO:7	0/10 †
	SEQ ID NO:8	0/10 †
	SEQ ID NO:9	0/10 †
	SEQ ID NO:13	10/10 †
	SEQ ID NO:14	10/10 †
	SEQ ID NO:10	10/10 ‡
	SEQ ID NO:11	10/10 ‡
	SEQ ID NO:12	10/10 ‡
	SEQ ID NO:15	10/10 ‡

† Capture oligonucleotides included the target-complementary sequences of SEQ ID NO:117, SEQ ID NO:118 and SEQ ID NO:119.

‡ Capture oligonucleotides included the target-complementary sequences of SEQ ID NO:120, SEQ ID NO:126 and SEQ ID NO:130.

The results presented in Table 11 showed that many of the primer combinations gave very high levels of WNV detectability, even at template levels lower than 1 PFU of viral equivalents per reaction. Even primer combinations that gave low, but measurable levels of WNV detectability in the results presented herein indicated successful amplification of WNV templates and established the combination as a useful component of a WNV nucleic acid amplification assay. Importantly, the results from these procedures showed that each of the primers complementary to one strand of the WNV nucleic acid could be paired with at least one of the primers complementary to the opposite strand of WNV nucleic acid to result in a highly sensitive amplification-based assay.

Table 12

Amplification of WNV Polynucleotide Sequences Using  
Various Primer Combinations

WNV-Complementary Sequence of the Promoter-Primer	Opposite Strand Primer	# Positive/ # Tested
SEQ ID NO:24	SEQ ID NO:10	9/10
	SEQ ID NO:11	10/10
	SEQ ID NO:12	9/10
	SEQ ID NO:15	9/10
SEQ ID NO:25	SEQ ID NO:10	10/10
	SEQ ID NO:11	10/10
	SEQ ID NO:12	10/10
	SEQ ID NO:15	10/10
SEQ ID NO:26	SEQ ID NO:10	10/10
	SEQ ID NO:11	10/10
	SEQ ID NO:12	10/10
	SEQ ID NO:15	9/10
SEQ ID NO:28	SEQ ID NO:10	10/10
	SEQ ID NO:11	10/10
	SEQ ID NO:12	10/10
	SEQ ID NO:15	10/10

The results presented in Table 12 further illustrate how the above-described capture oligonucleotides, probes and primers could be used in a highly sensitive assay for detecting WNV nucleic acids at very low levels of input template.

Example 3 describes the methods that identified primers useful for amplifying nucleic acids of the West Nile virus 3000 region.

### Example 3

#### Identification of Amplification Primers

Amplification reactions employing paired sets of primers specific for the 3000 region of WNV were carried out essentially as described under Example 2, except that promoter-primers having the WNV-complementary sequences presented in Table 4 were used in combination with opposite strand primers having the sequences presented in Table 3. Amplification reactions were conducted for the various primer combinations using 5  $\mu$ l or 1.4  $\mu$ l of a 1:10,000 dilution of the above-described viral lysate (each reaction contained less than 1 PFU viral equivalents). Nucleic acids underwent specimen processing in accordance with Example 2, using combinations of capture oligonucleotides that included the target-complementary



complementary sequences of SEQ ID NO:120, SEQ ID NO:126, and SEQ ID NO:130. Each capture oligonucleotide was used at a level of 2-5 pmoles/reaction in the target capture step.

Target nucleic acids and primers were heated to 60°C for 10 minutes and then cooled to 42°C

5 and amplification reactions conducted as described above. At the conclusion of the

amplification reactions, the entire reaction volumes were subjected to a hybridization assay

using a probe having the sequence of SEQ ID NO:100 (see Table 10). More particularly, the

probe was labeled with acridinium ester to a specific activity of about  $2 \times 10^8$  RLU/pmol and

then used in an amount equivalent to about  $1 \times 10^6$  to  $1 \times 10^7$  RLU for each hybridization

10 reaction. Trials were conducted using replicates of 10. To be judged as a positive result, the

chemiluminescent signal indicating probe hybridization must have exceeded 50,000 RLU in an assay.

Table 13 presents results from amplification procedures that were conducted using different combinations of primers to amplify nucleic acids of the 3000 region of WNV. Results

15 in the last column of the table show the number of positive trials and the number of replicate

trials used in the procedure. Unless indicated to the contrary, all reactions were carried out

using 5 µl of WNV lysate as the source of viral nucleic acids.

Amplification of WNV Polynucleotide Sequences Using  
Various Primer Combinations

WNV-Complementary Sequence of the Promoter-Primer	Opposite Strand Primer	# Positive/ # Tested
SEQ ID NO:53	SEQ ID NO:42	10/10 †
	SEQ ID NO:43	8/10 †
	SEQ ID NO:44	0/10 †
	SEQ ID NO:45	6/10 †
	SEQ ID NO:46	0/10 †
	SEQ ID NO:47	10/10 †
	SEQ ID NO:48	9/10 †
	SEQ ID NO:49	10/10 § ‡
	SEQ ID NO:50	10/10 § ‡
	SEQ ID NO:51	10/10 § ‡
SEQ ID NO:54	SEQ ID NO:42	4/10 †
	SEQ ID NO:43	1/10 †
	SEQ ID NO:44	0/10 †
	SEQ ID NO:45	0/10 †
	SEQ ID NO:46	0/10 †
	SEQ ID NO:47	10/10 †
	SEQ ID NO:48	8/10 †
	SEQ ID NO:49	8/10 †
	SEQ ID NO:50	5/10 †
	SEQ ID NO:51	2/10 †
SEQ ID NO:55	SEQ ID NO:42	0/10 †
	SEQ ID NO:43	0/10 †
	SEQ ID NO:44	0/10 †
	SEQ ID NO:45	0/10 †
	SEQ ID NO:46	0/10 †
	SEQ ID NO:47	9/10 †
	SEQ ID NO:48	0/10 †
	SEQ ID NO:49	0/10 †
	SEQ ID NO:50	9/10 †
	SEQ ID NO:51	10/10 †

§ WNV template was provided in 1.4 µl of lysate.

† Capture oligonucleotides included the target-complementary sequences of SEQ ID NO:117, SEQ ID NO:118 and SEQ ID NO:119.

‡ Capture oligonucleotides included the target-complementary sequences of SEQ ID NO:120, SEQ ID NO:126 and SEQ ID NO:130.

The results presented in Table 13 showed that many of the listed primer combinations

WO 2004/036190  
were useful for creating highly sensitive assays that involved amplification of PCT/US2003/033639  
acids. Indeed, it is contemplated that any of the listed primers complementary to one strand  
can be used in combination with any of the listed primers complementary to the opposite strand  
for amplifying WNV nucleic acids at some level of input template.

Example 4 describes the methods that identified primers useful for amplifying nucleic  
acids of the West Nile virus 3' non-coding region.

#### Example 4

##### Identification of Amplification Primers

Amplification reactions employing paired sets of primers specific for the 3' non-coding  
region of WNV were carried out essentially as described under the preceding Example, except  
that promoter-primers having the WNV-complementary sequences presented in Table 6 were  
used in combination with opposite strand primers having the sequences presented in Table 5.  
Amplification reactions were conducted for the various primer combinations using either 1.4  $\mu$ l  
or 0.14  $\mu$ l of a 1:10,000 dilution of the above-described viral lysate (each reaction contained  
less than 1 PFU viral equivalents). Nucleic acids underwent specimen processing using capture  
oligonucleotides having the target-complementary sequences of SEQ ID NO:118, SEQ ID  
NO:119 and SEQ ID NO:120 in combination, each at a level of 2-5 pmoles/reaction. Target  
nucleic acids and primers were heated to 60°C for 10 minutes and then cooled to 42°C and  
amplification reactions conducted as described above. At the conclusion of the amplification  
reactions, the entire reaction volumes were subjected to a hybridization assay using a probe  
having the sequence of SEQ ID NO:104 (see Table 10). More particularly, the probe was  
labeled with acridinium ester to a specific activity of about  $2 \times 10^8$  RLU/pmol and then used in  
an amount equivalent to about  $1 \times 10^6$  to  $1 \times 10^7$  RLU for each hybridization reaction. Trials  
were conducted using replicates of 10. To be judged as a positive result, the chemiluminescent  
signal indicating probe hybridization must have exceeded 50,000 RLU in an assay.

Table 14 presents results from amplification procedures that were conducted using  
different combinations of primers. Results in the last columns of the table show the number of  
positive trials and the number of replicate trials used in the procedures.

Amplification of WNV Polynucleotide Sequences Using  
Various Primer Combinations

WNV-Complementary Sequence of the Promoter-Primer	Opposite Strand Primer	# Positive/ # Tested
SEQ ID NO:75	SEQ ID NO:60	6/10 †
	SEQ ID NO:62	4/10 †
	SEQ ID NO:63	3/10 †
	SEQ ID NO:64	5/10 †
	SEQ ID NO:65	1/10 †
	SEQ ID NO:66	2/10 †
SEQ ID NO:76	SEQ ID NO:60	5/10 †
	SEQ ID NO:62	4/10 †
	SEQ ID NO:63	7/10 †
	SEQ ID NO:64	10/10 ‡
	SEQ ID NO:65	2/10 ‡
	SEQ ID NO:66	10/10 ‡
SEQ ID NO:77	SEQ ID NO:60	4/10 †
	SEQ ID NO:62	7/10 †
	SEQ ID NO:63	4/10 †
	SEQ ID NO:64	10/10 ‡
	SEQ ID NO:65	1/10 ‡
	SEQ ID NO:66	10/10 ‡

† : tested with 0.14 µl of a 1:10,000 dilution of WNV lysate

‡ : tested with 1.4 µl of a 1:10,000 dilution of WNV lysate

The results presented in Table 14 showed that the listed primer combinations were useful for creating highly sensitive assays that involved amplification of WNV nucleic acids. Indeed, it is contemplated that any of the listed primers complementary to one strand can be used in combination with any of the listed primers complementary to the opposite strand for amplifying WNV nucleic acids at some level of input template.

Notably, in all but a single instance, other promoter-primers that were used in combination with the opposite strand primers listed in Table 14 gave 0 positive/10 tests at the indicated target input level. More particularly, T7 promoter-primers that included WNV-complementary sequences given by the following oligonucleotides did not give good results when tested using the conditions given above when tested in combination with each of the opposite strand primers listed in Table 14: SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:80 and SEQ ID NO:81. If all primers were equivalent, then measurable results would have been

WO 2004/036190  
expected when using these primers, and that was not the case. Primers used in PCT/US2003/033639  
amplification procedures with extraordinary sensitivity were contained within the highly  
preferred domains of SEQ ID NO:73 and SEQ ID NO:74.

To further demonstrate flexibility in the assay design, additional procedures were  
conducted to show how more than one same-sense primer could be used in the amplification  
reaction without compromising assay sensitivity. Indeed, the ability to employ more than one  
same-sense primer in the assay represents one strategy for detecting WNV genetic variants.

Reactions for amplifying and detecting WNV in the 3' non-coding region were carried  
out substantially as described above, with the following minor modifications. Capture  
oligonucleotides used in the procedure included the target-complementary sequences of SEQ  
ID NO:134, SEQ ID NO:131 and SEQ ID NO:127. A promoter-primer that included the  
target-complementary sequence of SEQ ID NO:76 was present in all amplification reactions.  
Except as indicated in the table of results, all reactions included a primer having the sequence  
of SEQ ID NO:64 in combination with a second primer of the same sense that hybridized to the  
same strand of WNV nucleic acid. In one instance the primer having the sequence of SEQ ID  
NO:68 and the promoter-primer of SEQ ID NO:85, which included the target-complementary  
sequence of SEQ ID NO:76, were used for amplifying WNV nucleic acids in the absence of a  
third primer. A probe having the sequence of SEQ ID NO:111 was used in all instances for  
detecting amplicon production. Reactions were carried out in replicates of 10, and were primed  
using 0.33 µl of the 1:10,000 dilution of the above-described viral lysate (approximately 10-20  
copies of the viral target per reaction). To be judged as a positive result, the chemiluminescent  
signal indicating probe hybridization must have exceeded 50,000 RLU in an assay. Notably,  
these trials additionally included an HIV-1 internal control template and primers that did not  
substantially affect amplification or detection of the WNV target.

The results presented in Table 15 showed that each of the tested primer combinations  
facilitated amplification and detection of WNV nucleic acids.

Amplification of WNV Polynucleotide Sequences Using Combinations of  
Same-Sense Primers

Promoter-Primer	Opposite Strand Primer No. 1	Opposite Strand Primer No. 2	Testing Results
SEQ ID NO:85	SEQ ID NO:64	None	9/10
		SEQ ID NO:67	10/10
		SEQ ID NO:69	10/10
		SEQ ID NO:68	10/10
		SEQ ID NO:70	10/10
		SEQ ID NO:71	10/10
	None	SEQ ID NO:68	10/10

To illustrate still further the flexibility in the assay design, another procedure was conducted using the same set of capture oligonucleotides, and using multiple primers for generating WNV amplicons, but using different hybridization probes in the detection step. More specifically, capture oligonucleotides used in the procedure included the target-complementary sequences of SEQ ID NO:134, SEQ ID NO:131 and SEQ ID NO:127. A promoter-primer having the WNV-complementary sequence of SEQ ID NO:76 was used in combination with opposite strand primers having the sequences of SEQ ID NO:64 and SEQ ID NO:68. Amplification reactions were conducted using 1.4 µl of the above-described viral lysate as a template source. Detection reactions were carried out as described above using either of two different probes, one having the sequence of SEQ ID NO:107, and the other having the sequence of SEQ ID NO:114, each of these probes having been described above. Results from these procedures gave 10/10 positives using the probe of SEQ ID NO:107, and 18/18 positives using the probe of SEQ ID NO:114. This confirmed the utility of the hybridization probes and further demonstrated how elements of the amplification and detection procedure could be combined to result in sensitive assays. Notably, the probe of SEQ ID NO:114 was found in other procedures to give exceptionally reproducible results, even when biological samples undergoing testing were prepared by slightly different procedures. As noted above, the probe sequence of SEQ ID NO:114 differs slightly from the corresponding sequence contained in the probe domains defined by SEQ ID NO:101, SEQ ID NO:102 and SEQ ID

The following Example describes the methods used for testing candidate WNV capture oligonucleotides. In addition to the WNV-specific target capture, amplification primer, and probes described in this procedure, the reactions also tested the effect of including capture oligonucleotides specific for HIV-1, HCV and HBV analytes.

### Example 5

#### Detection of WNV Target Sequences Using Different

##### Capture Oligonucleotides

Aliquots of the WNV lysate used in the above-described procedures were dispersed in 400  $\mu$ l of lysis/capture reagent containing about 4 pmoles of each capture oligonucleotide and about 40  $\mu$ g of 0.7-1.05  $\mu$  paramagnetic particles (Seradyn, Indianapolis, IN) covalently linked to poly-(dT<sub>14</sub>). Capture oligonucleotides used in the procedure had the sequences given in Table 8. The lysis/capture reagent further included an HIV-1 internal amplification control template, HIV-1, HCV and HBV--specific capture oligonucleotides, and a 100 mM HEPES-buffered solution containing 294 mM lithium lauryl sulfate, 730 mM lithium chloride, and 50 mM lithium hydroxide. As stated above, a 5'-TTT-3' spacer sequence was interposed between the WNV-complementary sequence and the oligo-(dA) tail region for each of the capture oligonucleotides shown in Table 8. The mixtures were heated to 55-60°C for about 15-30 minutes, and then cooled to room temperature to allow hybridization. A magnetic field was applied to collect the particle complexes containing the immobilized capture oligonucleotide and WNV DNA using procedures such as those described by Wang in U.S. Patent No. 4,895,650. The particles were washed twice with 1 ml of a washing buffer (10 mM HEPES, 6.5 mM NaOH, 1 mM EDTA, 0.3% (v/v) ethanol, 0.02% (w/v) methyl-paraben, 0.01% (w/v) propyl-paraben, 150 mM NaCl, 0.1% (w/v) sodium lauryl sulfate). Washed particles were then resuspended in 75  $\mu$ l of the amplification reagent described under Example 2. This reagent included salts, nucleotides, ribonucleotides, WNV-specific primers. Some trials additionally included primers capable of amplifying an HIV-1 internal control template. The WNV target nucleic acid was then amplified, and the amplification products detected using a homogenous protection assay, essentially as described under Example 1 using the hybridization probe of SEQ ID NO:98 (see Table 10). Reactions that gave positive signals when hybridized with a probe specific for the internal control amplicon, or with a probe specific for the WNV amplicon, were scored as valid reactions. In order for a valid run to be considered positive for

WO 2004/036190  
the presence of WNV amplicons, the chemiluminescent signal indicating the presence of WNV must have exceeded 50,000 RLU in an assay. PCT/US2003/033639

Table 16 presents sample results correlating the identity of the WNV-specific capture oligonucleotide(s) and the ability of the system to amplify and detect WNV sequences efficiently. To achieve a positive result in the amplification reactions, the WNV capture oligonucleotide must have been able to act cooperatively with the amplification primers and probe(s) to capture WNV template nucleic acids, amplify the WNV template nucleic acids, and then detect the amplified nucleic acids.

Notably, promoter-primers used in this procedure and listed in Table 16 are identified by the complete sequence that included the T7 promoter. It is to be understood however, that the WNV-complementary portions of the promoter-primers represent essential sequences for performing amplification reactions by alternative protocols, such as the polymerase chain reaction, with the promoter sequence being optional. Thus, it is to be understood that some of the primers listed in Table 16 possessed optional promoter sequences, and that the corresponding primers which do not include the optional promoter represent the essential WNV-complementary sequences. These latter WNV-complementary sequences are useful in conjunction with opposite strand primers for amplifying WNV nucleic acids.



Efficiency of WNV Detection Using Different Combinations of  
Capture Oligonucleotides

Capture Oligonucleotide(s)	Amplification Primers	# Positive/# Tested
None	SEQ ID NO:35 SEQ ID NO:14	9/20
SEQ ID NO:118		17/20
SEQ ID NO:119		16/20
SEQ ID NO:117 SEQ ID NO:118 SEQ ID NO:119		14/20
SEQ ID NO:117		20/20
SEQ ID NO:120		20/20
SEQ ID NO:130		20/20
SEQ ID NO:121		20/20
SEQ ID NO:122		19/20
SEQ ID NO:123		20/20

The results presented in Table 16 confirmed that substantially all of the capture oligonucleotides that were tested, either alone or in combination, were useful in the WNV detection assay.

Like the NY99 strain that was used in the foregoing Examples, the Ugandan strain of West Nile virus is one of more than 100 known strains of the West Nile virus. Based on sequencing and phylogenetic analysis, the known viruses have been divided into two lineages — Lineage 1 and Lineage 2. Epidemiological data indicates that Lineage 2 strains, which have been isolated from either asymptomatic or mild febrile human cases, are somewhat less virulent than Lineage 1 strains. Lineage 1 strains have been associated with epidemics in which there have been human encephalitis cases and fatalities.

A key advantage of the above-described amplification systems was demonstrated using a “proficiency panel” of the West Nile virus Ugandan strain (an example of a Lineage 2 strain). Those having an ordinary level of skill in the art will appreciate that this strain is only distantly related at the nucleic acid level to the NY99 strain (an example of a Lineage 1 strain) that predominates in the United States. Thus, whether an assay can detect both the NY99 and

Example 6 describes the methods used for demonstrating that the Ugandan strain of West Nile virus was detected by the same assays that detected the NY99 strain.

#### Example 6

##### Amplification and Detection of the West Nile Virus Ugandan Strain

A proficiency panel of samples containing known amounts of the Ugandan strain of WNV in 800 to 1,000  $\mu$ l volumes of a human serum derivative was obtained from Boston Biomedica Inc. (MA). This panel consisted of a plurality of members, each containing either 0, 30, 100, 1,000 or 10,000 copies/ml of the WNV Ugandan strain RNA. Target-capture, amplification and detection procedures were performed essentially as described in the preceding Examples. In this Example the capture oligonucleotides having the target-complementary sequences of SEQ ID NO:120, SEQ ID NO:130 and SEQ ID NO:126 were used in combination with each other. In a preliminary procedure one of the panel members containing 10,000 copies/ml of the viral RNA was used to create a series of dilutions that contained either 10, 30, 100 or 300 copies of the viral nucleic acid. Amplification and detection reactions were performed using the oligonucleotide reagents listed in Table 17. In the present case the label on the probe having the sequence of SEQ ID NO:98 was located between positions 11 and 12; the label on the probe having the sequence of SEQ ID NO:100 was located between positions 9 and 10; and the label on the probe having the sequence of SEQ ID NO:104 was located between positions 6 and 7. When panel members were used for testing without prior dilution, a 500  $\mu$ l aliquot was used for a reaction that amplified the 3000 region of the target and the remaining volume of the panel member (amounting to less than 500  $\mu$ l) was used in a reaction that amplified the 3' non-coding region. Testing was restricted to these two regions because the volumes of undiluted panel members were limiting. Positive results were scored when the signal-to-noise ratio was at least 10.

Oligonucleotides Used for Amplifying and Detecting  
the Ugandan Strain of WNV

Target Region	Reagent	Oligonucleotide Identifier
5' Non-Coding Region	Promoter-Primer	SEQ ID NO:40
	Opposite-Strand Primer	SEQ ID NO:10
	Probe	SEQ ID NO:98
3000 Region	Promoter-Primer	SEQ ID NO:56
	Opposite-Strand Primer	SEQ ID NO:47
	Probe	SEQ ID NO:100
3' Non-Coding Region	Promoter-Primer	SEQ ID NO:85
	Opposite-Strand Primer	SEQ ID NO:64
	Probe	SEQ ID NO:104

Table 18 presents numerical results from this procedure. Precision among the results for each series of reactions conducted at a single target level was determined by calculating a coefficient of variability (%CV).

Table 18

Sensitivity Testing for Three Amplification Systems

using the Ugandan Strain of WNV

C/ml	5' Non-Coding Region			3000 Region			3' Non-Coding Region		
	Avg. RLU	%CV	% Pos	Avg. RLU	%CV	% Pos	Avg. RLU	%CV	% Pos
300	1,780,609 (N=5)	41	100	900,886 (N=5)	1	100	1,587,825 (N=5)	2	100
100	1,991,413 (N=10)	12	100	907,638 (N=10)	2	100	1,514,945 (N=10)	8	100
30	1,392,727 (N=10)	29	100	910,241 (N=10)	2	100	1,171,792 (N=10)	26	100
10	896,831 (N=10)	56	90	893,069 (N=10)	3	100	636,116 (N=10)	40	100
0	1,445 (N=5)	37	0	1,179 (N=5)	8	0	1,383 (N=5)	8	0



Proficiency Testing Verifies Sensitive Detection  
of WNV Ugandan Strain

Panel Member	WNV RNA Stock (copies/ml)	Results 3000 Region	Results 3' Non-Coding Region
QWN701.01	100	Positive	Positive
QWN701.02	0	Negative	Negative
QWN701.03	10,000	Not Tested	Not Tested
QWN701.04	30	Positive	Positive
QWN701.05	1,000	Positive	Positive
QWN701.06	300	Positive	Positive
QWN701.07	100	Positive	Positive
QWN701.08	0	Negative	Negative
QWN701.09	30	Positive	Positive
QWN701.10	1,000	Positive	Positive
QWN701.11	100	Positive	Positive
QWN701.12	10,000	Not Tested	Not Tested
QWN701.13	0	Negative	Negative
QWN701.14	30	Positive	Positive
QWN701.15	300	Positive	Positive
Negative Control	0	Negative	Negative
Negative Control	0	Negative	Negative
Negative Control	0	Negative	Negative
Negative Control	0	Negative	Negative
Negative Control	0	Negative	Negative

The results in Table 19 showed that the assays for amplifying and detecting sequences in the 3000 and 3' non-coding regions of West Nile virus detected the Ugandan strain of the viral RNA target down to 15 copies/reaction, or lower, without giving any false-positive

result WO 2004/036190,igs were consistent with the results presented in Table 1. PCT/US2003/033639

To illustrate further how the oligonucleotides described herein could be combined to produce highly sensitive assays, different combinations of capture oligonucleotides, primers and a probe were used for amplifying and detecting the West Nile virus Ugandan strain.

5 Procedures similar to those described above were used, except that capture oligonucleotides that included the target-complementary sequences of SEQ ID NO:117, SEQ ID NO:134 and SEQ ID NO:128 were used, the promoter primer of SEQ ID NO:85 included the target-complementary sequence of SEQ ID NO:76, the opposite-strand primer had the sequence of SEQ ID NO:64, and the above-described oligonucleotide having the sequence of SEQ ID

10 NO:111 was used as the probe. Additionally, samples containing 3, 1, 0.3 and 0.1 copies/ml of the virus were tested in replicates of 20 to generate data for accurately quantifying assay sensitivity. Regression analysis using the Probit function in SAS® System software (version 8.02) (Cary, NC) was used to calculate the 95% and 50% detection levels. Invalid reactions were not re-tested and were not included in the analysis of analytical sensitivity.

Table 20

Quantitative Sensitivity Testing using the Ugandan Strain of WNV

C/ml	% CV	% Positive	Analysis	
			95 % Detection Level in copies/ml (95% Confidence)	50 % Detection Level in copies/ml (95% Confidence)
300	5.9	100	9.0 (7.1 to 12.8)	4.5 (3.5 to 6.1)
100	33.9	100		
30	60.7	100		
10	98.4	95		
3	118	45		
1	NA	5		
0.3	128	0		
0.1	178	0		
0	129	0		

The results presented in Table 20 again showed that the Ugandan strain of West Nile virus was detected with excellent sensitivity in the amplified assay. More specifically, analysis of the results predicted 95% detection, using the nucleic acid amplification assay and end-point detection system, down to about 7-13 viral copies/ml, an amount corresponding to about 4-7 copies/reaction.

To further illustrate the versatility of the above-described analyte detection systems, amplicon production was monitored as a function of time in "real-time" amplification procedures. Amplicon-specific molecular beacons that were included in the amplification reactions provided a means for continuous monitoring of amplicon synthesis. Fluorescent emissions that increased with time indicated the production of amplicons that hybridized to the molecular beacon and caused a detectable transition to the "open" conformation of the probe.

Molecular beacons comprise nucleic acid molecules having a target-complementary sequence, an affinity pair (or nucleic acid "arms") that interact to form a "stem" structure by complementary base pairing in the absence of a target (i.e., the "closed" conformation), and a paired set of labels that interact when the probe is in the closed conformation. Those having an

ordinWO 2004/036120 in the art will understand that the target-complementary sequence  
WO 2004/036120 PCT/US2003/033639  
contained within the structure of a molecular beacon is generally in the form of a single-  
stranded "loop" region of the probe. Hybridization of the target nucleic acid and the target-  
complementary sequence of the probe causes the members of the affinity pair to separate,  
5 thereby shifting the probe to the open conformation. This shift is detectable by virtue of  
reduced interaction between the members of the label pair, which may be, for example, a  
fluorophore and a quencher. Molecular beacons are fully described in U.S. Patent No.  
5,925,517, the disclosure of this patent document being incorporated by reference herein.

Commercially available software was used to analyze time-dependent results obtained  
10 using molecular beacons that were specific for amplicons derived from: (1) the 5' non-coding  
region, (2) the 3000 region, and (3) the 3' non-coding region. Results from these analyses  
indicated a substantially linear relationship between the number of target copies included in an  
amplification reaction and the time at which the fluorescent signal exceeded a background  
threshold (i.e., "time-of-emergence" above background), as illustrated in Figure 3. As  
15 confirmed by the results presented below, these procedures were useful for quantifying analyte  
target amounts over a very broad range. More particularly, when known amounts of analyte  
polynucleotides are used as calibration standards, it is possible to determine the amount of  
analyte present in a test sample by comparing the measured time-of-emergence with the  
standard plot.

20 The fact that the amplification reaction used in the below-described procedures operated  
at constant temperature and without interruption for a separate detection step, so that  
amplification and detection took place simultaneously, imposed strict requirements on the  
molecular beacons. More specifically, success in the procedure required that the molecular  
beacon bind amplicon without inhibiting subsequent use of the amplicon as a template in the  
25 exponential amplification mechanism. Indeed, the finding that an amplification reaction could  
proceed efficiently in the presence of a molecular beacon indicated that interaction of the probe  
with its target did not irreversibly inhibit or poison the amplification reaction.

Example 7 describes procedures wherein molecular beacon probes, each labeled with an  
interactive fluorophore/quencher pair, were used for monitoring time-dependent amplicon  
30 production in TMA reactions. Although the molecular beacons described in this Example  
hybridized to only one strand of the amplified nucleic acid product, complementary probe  
sequences also would be expected to hybridize to the opposite nucleic acid strand, and so fall



## Example 7

### Real-Time Monitoring of Amplicon Production

Molecular beacons having binding specificity for the different WNV amplicons were synthesized by standard solid-phase phosphite triester chemistry using 3' quencher-linked controlled pore glass (CPG) and 5' fluorophore-labeled phosphoramidite on a Perkin-Elmer (Foster City, CA) EXPEDITE model 8909 automated synthesizer. Fluorescein was used as the fluorophore, and DABCYL was used as the quencher for construction of the molecular beacons. All of the molecular beacons were constructed using 2'-methoxy nucleotide analogs. The CPG and phosphoramidite reagents were purchased from Glen Research Corporation (Sterling, VA). Following synthesis, the probes were deprotected and cleaved from the solid support matrix by treatment with concentrated ammonium hydroxide (30%) for two hours at 60°C. Next, the probes were purified using polyacrylamide gel electrophoresis followed by HPLC using standard procedures that will be familiar to those having an ordinary level of skill in the art.

The nucleic acid targets used in the real-time amplification procedures were *in vitro* synthesized RNA transcripts of known concentration. The three *in vitro* synthesized WNV targets (a 5' non-coding region target, a 3000 region target, and a 3' non-coding region target) contained portions of the WNV genome that included sequences corresponding to, or complementary to each of the primers. Molecular beacons were used at a level of about 0.2 pmoles/ $\mu$ l (4 pmoles/reaction). Reactions for amplifying WNV nucleic acids were conducted using from as low as  $1.5 \times 10^1$  template copies/reaction up to as high as  $5 \times 10^9$  template copies/reaction.

Tubes containing 15  $\mu$ l of a buffered solution that included salts and reagents essentially as described under Example 2, a target polynucleotide, and a molecular beacon were first overlaid with 15  $\mu$ l of inert oil to prevent evaporation. The tubes were then incubated in a dry heat block for 10 minutes at 60°C to facilitate primer annealing. Primers for amplifying the 5' non-coding region of the WNV target had the target-complementary sequences of SEQ ID NO:28 (which was contained within the sequence of the SEQ ID NO:40 promoter-primer) and SEQ ID NO:10. Primers for amplifying the 3000 region of the WNV target had the target-complementary sequences of SEQ ID NO:53 (which was contained within the sequence of the promoter-primer of SEQ ID NO:56) and SEQ ID NO:47. Primers for amplifying the 3' non-

WO 2004/036190 PCT/US2003/033639  
 coding region of the WNV target had the target-complementary sequences of SEQ ID NO:79 (which was contained within the sequence of the promoter-primer of SEQ ID NO:85) and both SEQ ID NO:64 and SEQ ID NO:68. Following the 60°C incubation step, tubes were transferred to a 42°C heat block and then incubated for 10 minutes. Five-microliter aliquots of an enzyme reagent that included both MMLV reverse transcriptase and T7 RNA polymerase enzymes were added to each of the tubes using a repeat pipettor. Tubes were vortexed briefly and then transferred to a ROTORGENE-2000 (Corbett Research; Sydney, Australia) rotor that had been pre-warmed to 42°C. Amplification reactions were carried out at 42°C, fluorescence readings were taken every 30 seconds, and the results analyzed in real-time using standard software that was bundled with the ROTORGENE-2000 instrument.

#### Amplification in the 5' Non-Complementary Region

Table 21 presents the WNV target-complementary sequences contained in the loop portions of molecular beacons that were used for monitoring production of amplicons corresponding to the 5' non-coding region. Notably, the ninth position (occupied by an A residue) of the target-complementary loop sequence of SEQ ID NO:158 was mismatched to the amplicon product of the Ugandan strain of West Nile virus. All of the WNV-specific molecular beacons used in the procedure had target-complementary sequences that included 13-15 contiguous nucleotides contained within the sequences of SEQ ID NO:93 and SEQ ID NO:95, allowing for the presence of RNA and DNA equivalents. The target-complementary sequences presented in Table 21 were independently incorporated into the loop regions of molecular beacons.

**Table 21**

#### Target-Complementary Sequences of WNV-Specific Molecular Beacons (5' Non-Coding Region)

Sequence	SEQ ID NO:
GUCAAUAUGC UAAAA	SEQ ID NO:154
GUCAAUAUGC UAAA	SEQ ID NO:155
UGCAAUAUGC UAAA	SEQ ID NO:156
GAGCCGGGCUGUC	SEQ ID NO:157
AAACGCGGAAUGCCC	SEQ ID NO:158

The complete sequences of molecular beacons that contained the WNV-complementary

WO 2004/036190. PCT/US2003/033639  
 sequences presented in Table 21 appear in Table 22. With the exception of SEQ ID NO:162,  
 each of the molecular beacons included a 5' CCGAG arm sequence, and a 3' CUCGG arm  
 sequence appended to a WNV target-complementary sequence that appears in Table 21. The  
 molecular beacon having the sequence of SEQ ID NO:162 included a 5' GGCAC arm sequence  
 and a 3' GUGCC arm sequence appended to the loop portion of the probe. Notably, the loop  
 portion of the molecular beacon having the sequence of SEQ ID NO:161 included a WNV  
 target-complementary sequence and a single C residue appended to the 3' thereof, which was  
 not complementary to the WNV target. In all instances the WNV-complementary sequences  
 were positioned as loop regions within the molecular beacon structures. Thus, the last position  
 (occupied by a C residue) of the loop sequence of the molecular beacon having the sequence of  
 SEQ ID NO:161 was mismatched to the amplicon target sequence, and the ninth position of the  
 loop sequence (occupied by an A residue) in the molecular beacon having the sequence of SEQ  
 ID NO:163 was mismatched to the amplicon product of the Ugandan strain of West Nile virus.  
 Each of the molecular beacons used in the procedure included a fluorescein fluorophore at its  
 5'-end, and a DABCYL quencher moiety at its 3'-end. Sequences corresponding to  
 complementary arm structures are represented in Table 22 by underlining.

Table 22

Complete Sequences of WNV-Specific Molecular Beacons  
(5' Non-Coding Region)

Sequence	SEQ ID NO:
<u>CCGAG</u> -GUCAAUAUGC UAAAA- <u>CUCGG</u>	SEQ ID NO:159
<u>CCGAG</u> -GUCAAUAUGC UAAA- <u>CUCGG</u>	SEQ ID NO:160
<u>CCGAG</u> -UGUCAAUAUGC UAAAC- <u>CUCGG</u>	SEQ ID NO:161
<u>GGCAC</u> -GAGCCGGGCUGUC- <u>GUGCC</u>	SEQ ID NO:162
<u>CCGAG</u> -AAACGCGGAAUGCCC- <u>CUCGG</u>	SEQ ID NO:163

The results presented in Tables 23-25 confirmed that amplification reactions which  
 included one of the WNV-specific molecular beacons desirably produced a fluorescent signal  
 that increased with time until reaching a threshold level of detectability. Because different  
 amounts of WNV template were used for testing the various probes in different procedures, the  
 results of these procedures are presented in separate tables under which similar target amounts  
 are grouped. All results were based on reactions that were conducted in duplicate or triplicate.

With the exception of a single molecular beacon tested in this procedure (data not shown), each of the probes gave at least some level of time-dependent analyte detection. There was no attempt made to verify the integrity of the fluorescent labeling or probe synthesis in the case of the nonfunctional probe, and so the reason this probe did not give good results was not determined.

Significantly, the different molecular beacons tested in the procedure behaved somewhat differently in the real-time assay format. For example, reactions that included a molecular beacon having the target-complementary sequence of SEQ ID NO:155 gave exceedingly rapid detection of high target numbers and a strong linear relationship between the fluorescent signal and target amount on a logarithmic plot over the full range of input target levels tested (see Figure 3). Coefficients of variation (CVs) for the time-of-emergence readings obtained using this probe (see Table 23) were 3.3 % or less, thereby indicating very high levels of precision among the data points. Reactions that included a molecular beacon having the target-complementary sequence of SEQ ID NO:158 exhibited somewhat slower detection kinetics, but advantageously were capable of distinguishing low target levels from each other (see Table 24). These characteristics of the probes were reproduced when side-by-side reactions were conducted using molecular beacons containing the target-complementary sequences of SEQ ID NO:155 and SEQ ID NO:158. As indicated in Table 24, 32.2 minutes distinguished the time-of-emergence for reactions that included 15 and  $1.5 \times 10^7$  copies of the WNV template, and fully 10.7 minutes distinguished the time-of-emergence for reactions that included 15 and 150 copies of the WNV template when using the molecular beacon containing the WNV-complementary sequence of SEQ ID NO:158. It should be apparent that the slope of the line relating target copy number and time-of-emergence using this probe was particularly advantageous at the low target level range. Reactions that included a molecular beacon having the target-complementary sequence of SEQ ID NO:157 yielded a substantially linear relationship between input target copy number and time-of-emergence, but exhibited a slope that was somewhat more shallow when compared with the probe that included the target-complementary sequence of SEQ ID NO:158. Reactions that included a molecular beacon having the target-complementary sequence of SEQ ID NO:156 were carried out using levels of WNV target as low as about 4 copies/ reaction (see Table 25), and exhibited a strong, although again somewhat shallow linear relationship between measured time-of-emergence and the target copy number in the range of 4 -  $4.23 \times 10^3$  on a plot such as the one illustrated in Figure 3.

WO 2004/036190  
 Indeed, a difference of nearly 6 minutes distinguished the time-of-emergence of the reactions conducted at these extremes when using a probe comprising the target-complementary sequence of SEQ ID NO:156.

**Table 23**

Measured Time-of-Emergence During Real-Time Amplification

WNV Target copies/rxn	Time-of-Emergence Measured Using Molecular Beacons Containing Different Target- Complementary Sequences (minutes)	
	SEQ ID NO:154	SEQ ID NO:155
$5 \times 10^9$	9.0	5.9
$5 \times 10^8$	10.9	8.5
$5 \times 10^7$	12.2	10.5
$5 \times 10^6$	NT	13.0
$5 \times 10^5$	NT	15.2
$5 \times 10^4$	NT	17.2
$5 \times 10^3$	NT	19.5
$5 \times 10^2$	NT	22.0
$5 \times 10^1$	NT	25.3

"NT" = not tested  
 "ND" = not detected

Measured Time-of-Emergence During Real-Time Amplification

WNV Target copies/rxn	Time-of-Emergence Measured Using Molecular Beacons Containing Different Target-Complementary Sequences (minutes)	
	SEQ ID NO:157	SEQ ID NO:158
$1.5 \times 10^7$	27.67	28.73
$1.5 \times 10^6$	33.43	34.61
$1.5 \times 10^5$	38.3	40.54
$1.5 \times 10^4$	41.27	45.45
$1.5 \times 10^3$	44.59	47.96
$1.5 \times 10^2$	46.26	50.3
$1.5 \times 10^1$	52.34	60.97

"NT" = not tested

"ND" = not detected

Table 25

Measured Time-of-Emergence During Real-Time Amplification

WNV Target copies/rxn	Time-of-Emergence Measured Using Molecular Beacon Containing the Target-Complementary Sequence of SEQ ID NO:156 (minutes)
$4.23 \times 10^4$	37.65
$4.23 \times 10^3$	43.02
$4.23 \times 10^2$	45.38
$4.2 \times 10^1$	46.68
$4 \times 10^0$	48.9

"NT" = not tested

"ND" = not detected

Amplification in the 3000 Region

Table 26 presents the WNV target-complementary sequences contained in the loop portions of molecular beacons that were used for monitoring production of amplicons corresponding to the 3000 region. All of the WNV-specific molecular beacons had target-complementary sequences that included 10-20 contiguous bases contained in SEQ ID NO:99, allowing for the presence of nucleotide analogs and RNA and DNA equivalents. The target-complementary sequences presented in Table 26 were independently incorporated into the loop regions of molecular beacons.

Table 26

Target-Complementary Sequences of WNV-Specific Molecular Beacons(3000 Region)

Sequence	SEQ ID NO:
GGUCCUUCGCAAGAGG	SEQ ID NO:164
GGUCCUUCGCAAGAGGU	SEQ ID NO:165
GGUCCUUCGC	SEQ ID NO:166
AGGUCCUUCGCAAGAGGU	SEQ ID NO:167
GGUCCUUCGCAAGAGGUG	SEQ ID NO:168
GGUCCUUCGCAAGAGGUGG	SEQ ID NO:169
AGGUCCUUCGCAAGAGGUGG	SEQ ID NO:170

The complete sequences of molecular beacons that contained the WNV-complementary sequences presented in Table 26 appear in Table 27. Each of the molecular beacons included a 5' CCGAG arm sequence, and a 3' CUCGG arm sequence appended to its WNV target-complementary sequence. Additionally, each of the molecular beacons used in the procedure included a fluorescein fluorophore at its 5'-end, and a DABCYL quencher moiety at its 3'-end. Sequences corresponding to complementary arm structures are represented in Table 27 by underlining.

Complete Sequences of WNV-Specific Molecular Beacons  
(3000 Region)

Sequence	SEQ ID NO:
<u>CCGAG-GGUCCUUCGCAAGAGG-CUCGG</u>	SEQ ID NO:171
<u>CCGAG-GGUCCUUCGCAAGAGGU-CUCGG</u>	SEQ ID NO:172
<u>CCGAG-GGUCCUUCGC-CUCGG</u>	SEQ ID NO:173
<u>CCGAG-AGGUCCUUCGCAAGAGGU-CUCGG</u>	SEQ ID NO:174
<u>CCGAG-GGUCCUUCGCAAGAGGUG-CUCGG</u>	SEQ ID NO:175
<u>CCGAG-GGUCCUUCGCAAGAGGUGG-CUCGG</u>	SEQ ID NO:176
<u>CCGAG-AGGUCCUUCGCAAGAGGUGG-CUCGG</u>	SEQ ID NO:177

The results presented in Table 28 confirmed that amplification reactions which included one of the WNV-specific molecular beacons desirably produced a fluorescent signal that increased with time until reaching a threshold level of detectability. Again, the different molecular beacons behaved somewhat differently in the real-time assay format. For example, reactions that included a molecular beacon having the target-complementary sequence of SEQ. ID NO:167 gave extraordinarily rapid detection kinetics and a strong linear relationship between the fluorescent signal and target amount on a logarithmic plot over the full range of input target levels tested. Coefficients of variation (CVs) for the time-of-emergence readings obtained using this probe were 1.8 % or less, thereby indicating very high levels of precision among the data points. Reactions that included a molecular beacon having the target-complementary sequence of SEQ ID NO:165 exhibited different response characteristics that were somewhat less linear over the full range of target input levels tested. However, it was found that conventional curve-fitting of the numerical results obtained using this probe yielded a curve having an  $R^2$  value of greater than 0.99 with a slope that was substantially greater at low levels of input target when compared with high levels of input target. This advantageously permits more accurate quantitation of small differences between low target copy numbers.



Table 28

Measured Time-of-Emergence During Real-Time Amplification

WNV Target copies/rxn	Time-of-Emergence Measured Using Molecular Beacons Containing Different Target-Complementary Sequences (minutes)						
	SEQ ID NOs:						
	164	165	166	167	168	169	170
5x10 <sup>9</sup>	NT	NT	NT	NT	NT	NT	NT
5x10 <sup>8</sup>	10.9	NT	6.4	NT	NT	NT	NT
5x10 <sup>7</sup>	NT	NT	NT	NT	NT	NT	NT
5x10 <sup>6</sup>	NT	7.8	NT	3.6	7.4	6.7	7.2
5x10 <sup>5</sup>	NT	9.3	NT	4.9	8.8	8.1	8.5
5x10 <sup>4</sup>	NT	11.0	NT	6.3	10.7	9.7	10.4
5x10 <sup>3</sup>	NT	13.2	NT	7.9	12.2	11.7	12.3
5x10 <sup>2</sup>	NT	16.7	NT	9.6	14.2	13.6	14.0
5x10 <sup>1</sup>	NT	ND	NT	11.1	17.7	16.3	16.6

"NT" = not tested

"ND" = not detected

Amplification in the 3' Non-Coding Region

Table 29 presents the WNV target-complementary sequences contained in the loop portions of molecular beacons that were used for monitoring production of amplicons corresponding to the 3' non-coding region. The target-complementary sequences contained within the molecular beacons tested in this procedure included 12-18 contiguous nucleotides contained within the sequence of SEQ ID NO:101, more preferably within the sequence of SEQ ID NO:102, or still more preferably within the sequence of SEQ ID NO:103 or within the sequence of TAGACGGTGCTGCCTGCG (SEQ ID NO:178), allowing for the presence of nucleotide analogs and RNA and DNA equivalents.

The target-complementary sequences presented in Table 29 were independently incorporated into the loop regions of molecular beacons.

Target-Complementary Sequences of WNV-Specific Molecular Beacons  
(3' Non-Coding Region)

Sequence	SEQ ID NO:
CGGUGCUGCCUGCG	SEQ ID NO:179
UAGACGGUGCUG	SEQ ID NO:180
UAGACGGUGCUGCCUGCG	SEQ ID NO:181
UGAACAAAGCCGCGAAGU	SEQ ID NO:182
CUCAACCCCAGGAGGAC	SEQ ID NO:183

The complete sequences of molecular beacons that contained the WNV-complementary loop sequences presented in Table 29 appear in Table 30. Each of the molecular beacons included a 5' CCGAG arm sequence, and a 3' CUCGG arm sequence appended to its WNV target-complementary sequence. Additionally, each of the molecular beacons used in the procedure included a fluorescein fluorophore at its 5'-end, and a DABCYL quencher moiety at its 3'-end.

Table 30

Complete Sequences of WNV-Specific Molecular Beacons  
(3' Non-Coding Region)

Sequence	SEQ ID NO:
<u>CCGAG</u> -CGGUGCUGCCUGCG- <u>CUCGG</u>	SEQ ID NO:184
<u>CCGAG</u> -UAGACGGUGCUG- <u>CUCGG</u>	SEQ ID NO:185
<u>CCGAG</u> -UAGACGGUGCUGCCUGCG- <u>CUCGG</u>	SEQ ID NO:186
<u>CCGAG</u> -UGAACAAAGCCGCGAAGU- <u>CUCGG</u>	SEQ ID NO:187
<u>CCGAG</u> -CUCAACCCCAGGAGGAC- <u>CUCGG</u>	SEQ ID NO:188

The results presented in Table 31 again confirmed that amplification reactions which included one of the WNV-specific molecular beacons desirably produced a fluorescent signal that increased with time until reaching a threshold level of detectability. Notably, some of the results presented in Table 31 were obtained in different experiments. Nonetheless, it should be clear that some of the probes, such as the one that included the target-complementary sequence

WO 2004/036190 PCT/US2003/033639  
of SEQ ID NO:182, advantageously detected the WNV target with rapid kinetics, while other  
probes, such as the the one that included the target-complementary sequence of SEQ ID  
NO:179, exhibited slower detection kinetics. Each species of probe will be useful in a different  
particular application.

Table 31

Measured Time-of-Emergence During Real-Time Amplification

WNV Target copies/rxn	Time-of-Emergence Measured Using Molecular Beacons Containing Different Target-Complementary Sequences (minutes)				
	SEQ ID NOs:				
	179	180	181	182	183
$5 \times 10^9$	18.7	NT	NT	3.1	7.5
$5 \times 10^8$	27.8	15.4	15.4	5.0	14.3
$5 \times 10^7$	42.2	NT	NT	10.7	ND
$5 \times 10^6$	ND	NT	NT	ND	ND
$5 \times 10^5$	ND	NT	NT	NT	NT
$5 \times 10^4$	ND	NT	NT	NT	NT

"NT" = not tested

"ND" = not detected

1. A hybridization assay probe for detecting a nucleic acid, comprising:  
a probe sequence that comprises  
a target-complementary sequence of bases, and optionally  
one or more base sequences that are not complementary to said  
nucleic acid that is to be detected,  
wherein said target-complementary sequence of bases  
consists of 12-87 contiguous bases contained within the sequence  
of SEQ ID NO:101 or the complement thereof, allowing for the  
presence of RNA and DNA equivalents, nucleotide analogs and  
up to 10% base differences, and  
wherein said hybridization assay probe has a length of up  
to 100 bases.
2. The hybridization assay probe of Claim 1, wherein said target-complementary  
sequence of bases consists of 12-69 contiguous bases contained within the sequence of SEQ ID  
NO:102 or the complement thereof, allowing for the presence of RNA and DNA equivalents,  
nucleotide analogs and up to 10% base differences..
3. The hybridization assay probe of Claim 2, wherein said hybridization assay  
probe comprises said optional one or more base sequences that are not complementary to said  
nucleic acid that is to be detected.
4. The hybridization assay probe of Claim 3, further comprising a detectable label.
5. The hybridization assay probe of Claim 3, further comprising a fluorophore  
moiety and a quencher moiety, said hybridization assay probe being a molecular beacon.
6. The hybridization assay probe of Claim 5, wherein said target-complementary  
sequence of bases consists of any one of either SEQ ID NO:179, SEQ ID NO:180, SEQ ID  
NO:181, SEQ ID NO:182 or SEQ ID NO:183.
7. The hybridization assay probe of Claim 2, wherein said probe sequence does not  
comprise said optional one or more base sequences that are not complementary to said nucleic  
acid that is to be detected.
8. The hybridization assay probe of Claim 7, wherein said hybridization assay  
probe has a length of up to 69 bases.
9. The hybridization assay probe of Claim 8, further comprising a detectable label.

The hybridization assay probe of Claim 2, wherein said target-~~PCT/US2003/033639~~ sequence of bases consists of 18-52 contiguous bases contained within the sequence of SEQ ID NO:103 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

11. The hybridization assay probe of Claim 10, wherein said probe sequence does not comprise said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

12. The hybridization assay probe of Claim 11, further comprising a detectable label.

13. The hybridization assay probe of Claim 12, wherein said detectable label is selected from the group consisting of a chemiluminescent label and a fluorescent label.

14. The hybridization assay probe of Claim 10, wherein said hybridization assay probe has a length of up to 52 bases.

15. The hybridization assay probe of Claim 14, wherein said target-complementary sequence of bases consists of 18-22 contiguous bases contained within the sequence of SEQ ID NO:103 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and wherein said hybridization assay probe has a length of up to 22 bases.

16. The hybridization assay probe of Claim 1, wherein said probe sequence consists of SEQ ID NO:116.

17. The hybridization assay probe of Claim 15, wherein said probe sequence is selected from the group consisting of SEQ ID NO:106, SEQ ID NO:107, SEQ ID NO:108, SEQ ID NO:109, SEQ ID NO:110, SEQ ID NO:111 and SEQ ID NO:114.

18. A kit for amplifying a target nucleic acid sequence that may be present in a biological sample, comprising:

a first primer that comprises a 3' terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said first primer comprising 22 contiguous bases contained within SEQ ID NO:73, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences; and

a second primer that comprises a 3' terminal target-complementary sequence and

nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said second primer comprising 18 contiguous bases contained within SEQ ID NO:59, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

19. The kit of Claim 18, wherein said first primer and said second primer are each up to 60 bases in length.

20. The kit of Claim 18, wherein said 3' terminal target-complementary sequence of said first primer and said 3' terminal target-complementary sequence of said second primer are each up to 35 bases in length.

21. The kit of Claim 20, wherein said 3' terminal target-complementary sequence of said first primer is up to 24 bases in length.

22. The kit of Claim 20, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.

23. The kit of Claim 21, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.

24. The kit of Claim 23, wherein said first primer comprises said first primer upstream sequence.

25. The kit of Claim 24, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

26. The kit of Claim 23, wherein said 3' terminal target-complementary sequence of said first primer is selected from the group consisting of SEQ ID NO:75, SEQ ID NO:76 and SEQ ID NO:77, and wherein said 3' terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:60, SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70 and SEQ ID NO:71.

27. The kit of Claim 21, wherein said 3' terminal target-complementary sequence of said first primer comprises 22 contiguous bases contained within SEQ ID NO:74, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

28. The kit of Claim 27, wherein said 3' terminal target-complementary sequence of said second primer is up to 22 bases in length.

29. The kit of Claim 27, wherein said first primer comprises said first primer

30. The kit of Claim 29, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

31. A hybridization assay probe for detecting a nucleic acid, comprising:

a probe sequence that comprises

a target-complementary sequence of bases, and optionally

one or more base sequences that are not complementary to said nucleic acid that is to be detected,

wherein said target-complementary sequence of bases consists of 10-20 contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and

wherein said hybridization assay probe has a length of up to 100 bases.

32. The hybridization assay probe of Claim 31, wherein said length of said hybridization assay probe is up to 30 bases.

33. The hybridization assay probe of Claim 32, wherein said probe sequence comprises said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

34. The hybridization assay probe of Claim 33, further comprising a detectable label.

35. The hybridization assay probe of Claim 33, further comprising a fluorophore moiety and a quencher moiety, said hybridization assay probe being a molecular beacon.

36. The hybridization assay probe of Claim 31, wherein said probe sequence consists of 10-20 contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and does not comprise said optional one or more base sequences that are not complementary to said WNV nucleic acids.

37. The hybridization assay probe of Claim 36, wherein said hybridization assay probe has a length of up to 20 bases.

38. The hybridization assay probe of Claim 32, wherein said target-complementary

sequence of bases consists of 19-20 contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

39. The hybridization assay probe of Claim 38, wherein said probe sequence consists of 19-20 contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and does not comprise said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

40. The hybridization assay probe of Claim 38, further comprising a detectable label.

41. The hybridization assay probe of Claim 40, wherein said detectable label is selected from the group consisting of a chemiluminescent label and a fluorescent label.

42. The hybridization assay probe of Claim 38, wherein said target-complementary sequence of bases consists of 19-20 contiguous bases contained within the sequence of SEQ ID NO:99 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and wherein said hybridization assay probe has a length of up to 20 bases.

43. The hybridization assay probe of Claim 33, wherein said target-complementary sequence of bases acids is selected from the group consisting of SEQ ID NO:164, SEQ ID NO:165, SEQ ID NO:166, SEQ ID NO:167, SEQ ID NO:168, SEQ ID NO:169 and SEQ ID NO:170.

44. The hybridization assay probe of Claim 42, wherein said probe sequence is SEQ ID NO:100.

45. A kit for amplifying a target nucleic acid sequence that may be present in a biological sample, comprising:

a first primer that comprises a 3' terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said first primer comprising 22 contiguous bases contained within SEQ ID NO:52, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences; and

a second primer that comprises a 3' terminal target-complementary sequence and



optionally a second primer upstream sequence that is not complementary to said target

nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said second primer comprising 22 contiguous bases contained within SEQ ID NO:41, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

46. The kit of Claim 45, wherein said first primer and said second primer are each up to 60 bases in length.

47. The kit of Claim 45, wherein said 3' terminal target-complementary sequence of said first primer and said 3' terminal target-complementary sequence of said second primer are each up to 35 bases in length.

48. The kit of Claim 47, wherein said 3' terminal target-complementary sequence of said first primer is up to 26 bases in length.

49. The kit of Claim 47, wherein said 3' terminal target-complementary sequence of said second primer is up to 23 bases in length.

50. The kit of Claim 48, wherein said 3' terminal target-complementary sequence of said second primer is up to 23 bases in length.

51. The kit of Claim 50, wherein said 3' terminal target-complementary sequence of said first primer is selected from the group consisting of SEQ ID NO:53, SEQ ID NO:54 and SEQ ID NO:55, and wherein said 3' terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:42, SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:43, SEQ ID NO:49, SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:50, SEQ ID NO:51 and SEQ ID NO:46.

52. The kit of Claim 48, wherein said 3' terminal target-complementary sequence of said second primer is up to 23 bases in length.

53. The kit of Claim 52, wherein said first primer comprises said first primer upstream sequence.

54. The kit of Claim 53, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.

55. A hybridization assay probe for detecting a nucleic acid, comprising:

a probe sequence that comprises

a target-complementary sequence of bases, and optionally

one or more base sequences that are not complementary to said nucleic

wherein said target-complementary sequence of bases consists of 13-37 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and wherein said hybridization assay probe has a length of up to 100 bases.

56. The hybridization assay probe of Claim 55, wherein said length of said hybridization assay probe is up to 37 bases.

57. The hybridization assay probe of Claim 56, wherein said hybridization assay probe comprises said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

58. The hybridization assay probe of Claim 57, further comprising a detectable label.

59. The hybridization assay probe of Claim 57, further comprising a fluorophore moiety and a quencher moiety, said hybridization assay probe being a molecular beacon.

60. The hybridization assay probe of Claim 55, wherein said probe sequence consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and does not comprise said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

61. The hybridization assay probe of Claim 56, wherein said target-complementary sequence of bases consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

62. The hybridization assay probe of Claim 61, wherein said probe sequence consists of 20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, and does not comprise said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected.

63. The hybridization assay probe of Claim 61, further comprising a detectable label.

64. The hybridization assay probe of Claim 63, wherein said detectable label is selected from the group consisting of a chemiluminescent label and a fluorescent label.

65. The hybridization assay probe of Claim 61, wherein said target-complementary sequence of bases consists of 13-20 contiguous bases contained within the sequence of SEQ ID NO:95 or the complement thereof, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences, wherein said probe sequence does not comprise said optional one or more base sequences that are not complementary to said nucleic acid that is to be detected, and wherein said hybridization assay probe has a length of up to 20 bases.

66. The hybridization assay probe of Claim 57, wherein said target-complementary sequence of bases is selected from the group consisting of SEQ ID NO:154, SEQ ID NO:155, SEQ ID NO:156, SEQ ID NO:157, and SEQ ID NO:158.

67. The hybridization assay probe of Claim 65, wherein said probe sequence is SEQ ID NO:98.

68. A kit for amplifying a target nucleic acid sequence that may be present in a biological sample, comprising:

a first primer that comprises a 3' terminal target-complementary sequence and optionally a first primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said first primer comprising 20 contiguous bases contained within SEQ ID NO:16, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences; and

a second primer that comprises a 3' terminal target-complementary sequence up to 30 bases in length and optionally a second primer upstream sequence that is not complementary to said target nucleic acid sequence that is to be amplified, said 3' terminal target-complementary sequence of said second primer comprising 20 contiguous bases contained within SEQ ID NO:1, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

69. The kit of Claim 68, wherein said first primer and said second primer are each up to 60 bases in length.

70. The kit of Claim 68, wherein said 3' terminal target-complementary sequence of said first primer is up to 35 bases in length.

71. The kit of Claim 70, wherein said 3' terminal target-complementary sequence of said first primer is up to 24 bases in length.

72. The kit of Claim 70, wherein said 3' terminal target-complementary sequence of said second primer is up to 24 bases in length.

73. The kit of Claim 71, wherein said 3' terminal target-complementary sequence of said second primer is up to 24 bases in length.

74. The kit of Claim 70, wherein said 3' terminal target-complementary sequence of said second primer is up to 26 bases in length and comprises 20 contiguous bases contained within SEQ ID NO:2, allowing for the presence of RNA and DNA equivalents, nucleotide analogs and up to 10% base differences.

75. The kit of Claim 74, wherein said 3' terminal target-complementary sequence of said first primer is up to 24 bases in length.

76. The kit of Claim 74, wherein said 3' terminal target-complementary sequence of said second primer is up to 24 bases in length.

77. The kit of Claim 75, wherein said 3' terminal target-complementary sequence of said second primer is up to 24 bases in length.

78. The kit of Claim 75, wherein said 3' terminal target-complementary sequence of said first primer is selected from the group consisting of SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26 and SEQ ID NO:28.

79. The kit of Claim 75, wherein said 3' terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:13 and SEQ ID NO:15.

80. The kit of Claim 78, wherein said 3' terminal target-complementary sequence of said second primer is selected from the group consisting of SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:13 and SEQ ID NO:15.

81. The kit of Claim 80, wherein said first primer comprises said first primer upstream sequence.

82. The kit of Claim 81, wherein said first primer upstream sequence comprises a promoter sequence for T7 RNA polymerase.




FIG1

2/3





FIG. 2

3/3

**FIG. 3**

## SEQUENCE LISTING

<110> Linnen, Jeffrey M.  
Pollner, Reinhold B.  
Wu, Wen  
Dennis, Geoffrey G.  
Darby, Paul M.

<120> Compositions and Methods for Detecting  
West Nile Virus

<130> GP140-04.UT

<150> 60/418,891

<151> 2002-10-16

<150> 60/429,006

<151> 2002-11-25

<150> 60/449,810

<151> 2003-02-24

<160> 196

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 58

<212> DNA

<213> West Nile Virus

<400> 1

caattaacac agtgcgagct gtttcttagc acgaagatct cgatgtctaa gaaaccag

58

<210> 2

<211> 26

<212> DNA

<213> West Nile Virus

<400> 2

gaagatctcg atgtctaaga aaccag

26

<210> 3

<211> 27

<212> DNA

<213> West Nile Virus

<400> 3

caattaacac agtgcgagct gtttctt

27

<210> 4

<211> 24

<212> DNA

<213> West Nile Virus

<400> 4

caattaacac agtgcgagct gttt

24

<210> 5

<211> 24

<212> DNA

<213> West Nile Virus



<220>  
<221> modified\_base  
<222> (11)...(11)  
<223> I  
  
<400> 5  
caattaacac ngtgcgagct gttt 24  
  
<210> 6  
<211> 23  
<212> DNA  
<213> West Nile Virus  
  
<400> 6  
taacacagtgcgagctgttt ctt 23  
  
<210> 7  
<211> 23  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> modified\_base  
<222> (7)...(7)  
<223> I  
  
<400> 7  
taacacngtg cgagctgttt ctt 23  
  
<210> 8  
<211> 20  
<212> DNA  
<213> West Nile Virus  
  
<400> 8  
cgagctgttt cttagcacga 20  
  
<210> 9  
<211> 21  
<212> DNA  
<213> West Nile Virus  
  
<400> 9  
cgagctgttt cttagcacga a 21  
  
<210> 10  
<211> 24  
<212> DNA  
<213> West Nile Virus  
  
<400> 10  
gaagatctcg atgtctaaga aacc 24  
  
<210> 11  
<211> 23  
<212> DNA  
<213> West Nile Virus  
  
<400> 11  
aagatctcga tgtctaagaa acc 23  
  
<210> 12  
<211> 22  
<212> DNA

<400> 12  
agatctcgat gtctaagaaa cc 22  
  
<210> 13  
<211> 22  
<212> DNA  
<213> West Nile Virus  
  
<400> 13  
gatctcgatg tctaagaaac ca 22  
  
<210> 14  
<211> 21  
<212> DNA  
<213> West Nile Virus  
  
<400> 14  
gatctcgatg tctaagaaac c 21  
  
<210> 15  
<211> 22  
<212> DNA  
<213> West Nile Virus  
  
<400> 15  
atctcgatgt ctaagaaacc ag 22  
  
<210> 16  
<211> 69  
<212> DNA  
<213> West Nile Virus  
  
<400> 16  
acatagccct cttcagtcca atcaaggaca acacgcgggg cattccgcgt tttagcatat 60  
tgacagccc 69  
  
<210> 17  
<211> 21  
<212> DNA  
<213> West Nile Virus  
  
<400> 17  
gttttagcat attgacagcc c 21  
  
<210> 18  
<211> 20  
<212> DNA  
<213> West Nile Virus  
  
<400> 18  
gttttagcat attgacagcc 20  
  
<210> 19  
<211> 21  
<212> DNA  
<213> West Nile Virus  
  
<400> 19  
ttccgcgttt tagcatattg a 21  
  
<210> 20  
<211> 21

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 20

attccgcggtt ttagcatatt g

21

&lt;210&gt; 21

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 21

atcaaggaca acacgcgggg cat

23

&lt;210&gt; 22

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; modified base

&lt;222&gt; (12)...(12)

&lt;223&gt; I

&lt;400&gt; 22

atcaaggaca anacgcgggg cat

23

&lt;210&gt; 23

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 23

cctcttcagt ccaatcaagg acaa

24

&lt;210&gt; 24

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 24

agccctcttc agtccaatca agga

24

&lt;210&gt; 25

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 25

tagccctctt cagtccaatc aagg

24

&lt;210&gt; 26

&lt;211&gt; 24

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 26

atagccctct tcagtccaat caag

24

&lt;210&gt; 27

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

<400> 27  
tagccctctt cagtccaatc aa

22

<210> 28  
<211> 24  
<212> DNA  
<213> West Nile Virus

<400> 28  
acatagccct cttcagtcca atca

24

<210> 29  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature  
<222> (28)...(48)  
<223> WNV-complementary sequence

<400> 29  
aatttaatac gactcactat agggagagtt ttagcatatt gacagccc

48

<210> 30  
<211> 47  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature  
<222> (28)...(47)  
<223> WNV-complementary sequence

<400> 30  
aatttaatac gactcactat agggagagtt ttagcatatt gacagcc

47

<210> 31  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter-primer

<221> misc\_feature  
<222> (28)...(48)  
<223> WNV-complementary sequence

<400> 31  
aatttaatac gactcactat agggagattc cgcgttttag catattga

48

<210> 32  
<211> 48

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(48)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 32

aatttaatac gactcactat agggagaatt ccgçgtttta gcatattg

48

&lt;210&gt; 33

&lt;211&gt; 50

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(50)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 33

aatttaatac gactcactat agggagaatc aaggacaça cgçggggcat

50

&lt;210&gt; 34

&lt;211&gt; 50

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(50)

&lt;223&gt; WNV-complementary sequence

&lt;221&gt; modified\_base

&lt;222&gt; (39)...(39)

&lt;223&gt; I

&lt;400&gt; 34

aatttaatac gactcactat agggagaatc aaggacaana cgçggggcat

50

&lt;210&gt; 35

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

<223> WNV-complementary sequence

<400> 35

aatttaatac gactcactat agggagaact cttcagtcca atcaaggaca a

51

<210> 36

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)...(27)

<223> T7 promoter sequence

<221> misc\_feature

<222> (28)...(51)

<223> WNV-complementary sequence

<400> 36

aatttaatac gactcactat agggagaagc cctcttcagt ccaatcaagg a

51

<210> 37

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)...(27)

<223> T7 promoter sequence

<221> misc\_feature

<222> (28)...(51)

<223> WNV-complementary sequence

<400> 37

aatttaatac gactcactat agggagatag ccctcttcag tccaatcaag g

51

<210> 38

<211> 51

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)...(27)

<223> T7 promoter sequence

<221> misc\_feature

<222> (28)...(51)

<223> WNV-complementary sequence

<400> 38

aatttaatac gactcactat agggagaata gccctcttca gtccaatcaa g

51

<210> 39

<211> 49

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(49)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 39

aatttaatac gactcactat agggagatag ccctcttcag tccaatcaa

49

&lt;210&gt; 40

&lt;211&gt; 51

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(51)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 40

aatttaatac gactcactat agggagaaca tagccctctt cagtccaatc a

51

&lt;210&gt; 41

&lt;211&gt; 49

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 41

ttgacccttt tcagttgggc cttctggtcg tggtcttggc caccagga

49

&lt;210&gt; 42

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 42

ttgacccttt tcagttgggc ctt

23

&lt;210&gt; 43

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 43

cttttcagtt gggccttctg gt

22

&lt;210&gt; 44

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 44

agttgggcct tctggtcgtg tt

22

&lt;210&gt; 45

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

<400> 45  
tggtcgtgtt cttggccacc ca

22

<210> 46  
<211> 22  
<212> DNA  
<213> West Nile Virus

<400> 46  
tcgtgttctt ggccacccag ga

22

<210> 47  
<211> 23  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (5)...(5)  
<223> I

<400> 47  
ttganccttt tcagttgggc ctt

23

<210> 48  
<211> 23  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (15)...(15)  
<223> I

<400> 48  
ttgacccttt tcagntgggc ctt

23

<210> 49  
<211> 22  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (9)...(9)  
<223> I

<400> 49  
cttttcagnt ggccttctg gt

22

<210> 50  
<211> 22  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (11)...(11)  
<223> I

<400> 50  
tggtcgtgtt nttggccacc ca

22

<210> 51



&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; modified\_base

&lt;222&gt; (12)...(12)

&lt;223&gt; I

&lt;400&gt; 51

tggtcgtgtt cntggccacc ca

22

&lt;210&gt; 52

&lt;211&gt; 26

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 52

atagctggca tgctgatctt ggctgt

26

&lt;210&gt; 53

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 53

ctggcatgct gatcttggct gt

22

&lt;210&gt; 54

&lt;211&gt; 23

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 54

atagctggca tgctgatctt ggc

23

&lt;210&gt; 55

&lt;211&gt; 22

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;400&gt; 55

atagctggca tgctgatctt gg

22

&lt;210&gt; 56

&lt;211&gt; 49

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(49)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 56

aatttaatac gactcactat agggagactg gcatgctgat cttggctgt

49

&lt;210&gt; 57

&lt;211&gt; 50

&lt;212&gt; DNA

<220>  
 <221> misc\_feature  
 <222> (1)...(27)  
 <223> T7 promoter sequence

<221> misc\_feature  
 <222> (28)...(50)  
 <223> WNV-complementary sequence

<400> 57  
 aatttaatac gactcactat agggagaata gctggcatgc tgatcttggc 50

<210> 58  
 <211> 49  
 <212> DNA  
 <213> Artificial Sequence

<220>  
 <221> misc\_feature  
 <222> (1)...(27)  
 <223> T7 promoter sequence

<221> misc\_feature  
 <222> (28)...(49)  
 <223> WNV-complementary sequence

<400> 58  
 aatttaatac gactcactat agggagaata gctggcatgc tgatcttgg 49

<210> 59  
 <211> 31  
 <212> DNA  
 <213> West Nile Virus

<400> 59  
 tccgccaccg gaagttgagt agacggtgct g 31

<210> 60  
 <211> 19  
 <212> DNA  
 <213> West Nile Virus

<400> 60  
 tccgccaccg gaagttgag 19

<210> 61  
 <211> 19  
 <212> DNA  
 <213> West Nile Virus

<220>  
 <221> modified\_base  
 <222> (1)...(1)  
 <223> I

<400> 61  
 nccgccaccg gaagttgag 19

<210> 62  
 <211> 20  
 <212> DNA  
 <213> West Nile Virus

<400> 62  
tccgccaccg gaagttgagt

20

<210> 63  
<211> 21  
<212> DNA  
<213> West Nile Virus

<400> 63  
tccgccaccg gaagttgagt a

21

<210> 64  
<211> 18  
<212> DNA  
<213> West Nile Virus

<400> 64  
cgccaccgga agttgagt

18

<210> 65  
<211> 18  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified base  
<222> (1)...(1)  
<223> I

<400> 65  
ngccaccgga agttgagt

18

<210> 66  
<211> 19  
<212> DNA  
<213> West Nile Virus

<400> 66  
cgccaccgga agttgagta

19

<210> 67  
<211> 21  
<212> DNA  
<213> West Nile Virus

<400> 67  
ggaagttgag tagacggtgc t

21

<210> 68  
<211> 22  
<212> DNA  
<213> West Nile Virus

<400> 68  
ggaagttgag tagacggtgc tg

22

<210> 69  
<211> 20  
<212> DNA  
<213> West Nile Virus

<400> 69  
gaagttgagt agacggtgct

20

<210> 70  
<211> 21  
<212> DNA  
<213> West Nile Virus

<400> 70  
gaagttgagt agacggtgct g 21

<210> 71  
<211> 20  
<212> DNA  
<213> West Nile Virus

<400> 71  
aagttgagta gacggtgctg 20

<210> 72  
<211> 70  
<212> DNA  
<213> West Nile Virus

<400> 72  
tccgagacgg ttctgagggc ttacatggat cacttgcag ctttgtcac ccagtcctcc 60  
tggggttgag 70

<210> 73  
<211> 48  
<212> DNA  
<213> West Nile Virus

<400> 73  
tccgagacgg ttctgagggc ttacatggat cacttgcag ctttgttc 48

<210> 74  
<211> 24  
<212> DNA  
<213> West Nile Virus

<400> 74  
tccgagacgg ttctgagggc ttac 24

<210> 75  
<211> 24  
<212> DNA  
<213> West Nile Virus

<400> 75  
tccgagacgg ttctgagggc ttac 24

<210> 76  
<211> 23  
<212> DNA  
<213> West Nile Virus

<400> 76  
tccgagacgg ttctgagggc tta 23

<210> 77  
<211> 22  
<212> DNA  
<213> West Nile Virus

<400> 77  
tccgagacgg ttctgagggc tt 22

<210> 78  
<211> 20  
<212> DNA  
<213> West Nile Virus

<400> 78  
ccagtcctcc tgggggttgag 20

<210> 79  
<211> 22  
<212> DNA  
<213> West Nile Virus

<400> 79  
accagtcct cctgggggttg ag 22

<210> 80  
<211> 21  
<212> DNA  
<213> West Nile Virus

<400> 80  
accagtcct cctgggggttg a 21

<210> 81  
<211> 20  
<212> DNA  
<213> West Nile Virus

<400> 81  
accagtcct cctgggggttg 20

<210> 82  
<211> 20  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (7)...(7)  
<223> I

<221> modified\_base  
<222> (10)...(10)  
<223> I

<400> 82  
gctacancan gtggggtcct 20

<210> 83  
<211> 20  
<212> DNA  
<213> West Nile Virus

<220>  
<221> modified\_base  
<222> (10)...(10)  
<223> I

<400> 83  
gctacaacan gtggggtcct 20

<210> 84  
<211> 51

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(51)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 84

aatttaatac gactcactat agggagatcc gagacggttc tgagggtta c

51

&lt;210&gt; 85

&lt;211&gt; 50

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(50)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 85

aatttaatac gactcactat agggagatcc gagacggttc tgagggtta

50

&lt;210&gt; 86

&lt;211&gt; 49

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(49)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 86

aatttaatac gactcactat agggagatcc gagacggttc tgagggtt

49

&lt;210&gt; 87

&lt;211&gt; 47

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; T7 promoter sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (28)...(47)

&lt;223&gt; WNV-complementary sequence

&lt;400&gt; 87

<210> 88  
<211> 49  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature  
<222> (28)...(49)  
<223> WNV-complementary sequence

<400> 88  
aatttaatac gactcactat agggagaacc cagtcctcct ggggttgag

49

<210> 89  
<211> 48  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature  
<222> (28)...(48)  
<223> WNV-complementary sequence

<400> 89  
aatttaatac gactcactat agggagaacc cagtcctcct ggggttga

48

<210> 90  
<211> 47  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature  
<222> (28)...(47)  
<223> WNV-complementary sequence

<400> 90  
aatttaatac gactcactat agggagaacc cagtcctcct ggggttg

47

<210> 91  
<211> 47  
<212> DNA  
<213> Artificial Sequence

<220>  
<221> misc\_feature  
<222> (1)...(27)  
<223> T7 promoter sequence

<221> misc\_feature

<222> (28)...(47)

<223> WNV-complementary sequence

<221> modified base

<222> (34)...(34)

<223> I

<221> modified base

<222> (37)...(37)

<223> I

<400> 91

aatttaatac gactcactat agggagagct acancangtg gggtcct

47

<210> 92

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<221> misc\_feature

<222> (1)...(27)

<223> T7 promoter sequence

<221> misc\_feature

<222> (28)...(47)

<223> WNV-complementary sequence

<221> modified base

<222> (37)...(37)

<223> I

<400> 92

aatttaatac gactcactat agggagagct acaacangtg gggtcct

47

<210> 93

<211> 65

<212> DNA

<213> West Nile Virus

<400> 93

tgtctaagaa accaggaggg cccggcaaga gccgggctgt caatatgcta aaacgcggaa  
tgccc

60

65

<210> 94

<211> 25

<212> DNA

<213> West Nile Virus

<400> 94

tgtctaagaa accaggaggg cccgg

25

<210> 95

<211> 37

<212> DNA

<213> West Nile Virus

<400> 95

gagccgggct gtcaatatgc taaaacgcgg aatgccc

37

<210> 96

<211> 21

<212> DNA

<213> West Nile Virus



<220>  
<221> misc\_feature  
<222> (1)...(21)  
<223> 2'-OMe nucleotide analogs  
  
<400> 96  
tgtctaagaa accaggagg c 21  
  
<210> 97  
<211> 18  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs  
  
<400> 97  
gaaaccagga gggcccgg 18  
  
<210> 98  
<211> 20  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs  
  
<400> 98  
gctgtcaata tgctaaaacg 20  
  
<210> 99  
<211> 20  
<212> DNA  
<213> West Nile Virus  
  
<400> 99  
aggtccttcg caagaggtgg 20  
  
<210> 100  
<211> 19  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs  
  
<400> 100  
ggtccttcgc aagaggtgg 19  
  
<210> 101  
<211> 87  
<212> DNA  
<213> West Nile Virus  
  
<400> 101  
gagtagacgg tgctgcctgc gactcaaccc caggaggact gggngaacaa agccgcgaag 60  
tgatccatgt aagccctcag aaccgtc 87

<210> 102  
<211> 69  
<212> DNA  
<213> West Nile Virus

<400> 102  
gagtagacgg tgctgcctgc gactcaaccc caggaggact gggatgaaca agccgcgaag 60  
tgatccatg 69

<210> 103  
<211> 52  
<212> DNA  
<213> West Nile Virus

<400> 103  
tgcgactcaa cccaggagg actgggtgaa caaagccgcg aagtgatcca tg 52

<210> 104  
<211> 21  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(21)  
<223> 2'-OMe nucleotide analogs

<400> 104  
gagtagacgg tgctgcctgc g 21

<210> 105  
<211> 19  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 105  
gtagacggtg ctgcctgcg 19

<210> 106  
<211> 22  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs

<400> 106  
tgcgactcaa cccaggagg ac 22

<210> 107  
<211> 18  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(18)

<400> 107  
tgcgactcaa ccccagga 18

<210> 108  
<211> 20  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs

<400> 108  
cgactcaacc ccaggaggac 20

<210> 109  
<211> 19  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 109  
gactcaaccc caggaggac 19

<210> 110  
<211> 18  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs

<400> 110  
gactcaaccc caggagga 18

<210> 111  
<211> 18  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs

<400> 111  
actcaacccc aggaggac 18

<210> 112  
<211> 19  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature

<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 112  
caggaggacu gggugaaca 19

<210> 113  
<211> 19  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 113  
gaggacuggg ugaacaaag 19

<210> 114  
<211> 20  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs

<400> 114  
gtgaacaaag ctgcgaagtg 20

<210> 115  
<211> 20  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs

<400> 115  
aagccgcgaa gtgatccatg 20

<210> 116  
<211> 19  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 116  
gtaagccctc agaaccgtc 19

<210> 117  
<211> 23  
<212> RNA  
<213> West Nile Virus

<220>

<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 117  
aauccucaca aacacuacua agu 23

<210> 118  
<211> 23  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 118  
aagaacgcca agagagccaa cac 23

<210> 119  
<211> 26  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(26)  
<223> 2'-OMe nucleotide analogs

<400> 119  
ccucuuuucu uuuguuuunga gcuccg 26

<210> 120  
<211> 23  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 120  
aatcctcaca aacactacta agt 23

<210> 121  
<211> 22  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs

<400> 121  
cctcctctttt tcttttgttt tg 22

<210> 122  
<211> 25  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(25)  
<223> 2'-OMe nucleotide analogs  
  
<400> 122  
ccuccucuuu ucuuuuguuu ugagc 25  
  
<210> 123  
<211> 25  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(25)  
<223> 2'-OMe nucleotide analogs  
  
<400> 123  
cctcctctttt tcttttgttt tgagc 25  
  
<210> 124  
<211> 23  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 124  
uucaucgcug uuuguuuguu cac 23  
  
<210> 125  
<211> 23  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 125  
tgtgtctgca ctgtcagtga cct 23  
  
<210> 126  
<211> 23  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 126  
ugugucugca cugucaguga ccu 23  
  
<210> 127  
<211> 21  
<212> RNA  
<213> West Nile Virus

<221> misc\_feature  
<222> (1)...(21)  
<223> 2'-OMe nucleotide analogs  
  
<400> 127  
guuuugucuu ccauccauuc a 21  
  
<210> 128  
<211> 22  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs  
  
<400> 128  
guuuugucuu ccauccauuc au 22  
  
<210> 129  
<211> 25  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(25)  
<223> 2'-OMe nucleotide analogs  
  
<400> 129  
ucucucucuu ucccaucaug uugua 25  
  
<210> 130  
<211> 22  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs  
  
<400> 130  
ccuccucuuu ucuuuuguuu ug 22  
  
<210> 131  
<211> 23  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 131  
ccaacugauc caaaguccca agc 23  
  
<210> 132  
<211> 24  
<212> RNA  
<213> West Nile Virus

<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 132  
acccuccaa cugaucaaa gucc 24  
  
<210> 133  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 133  
gaacaccccu ccaacugauc caaa 24  
  
<210> 134  
<211> 20  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs  
  
<400> 134  
gcagguccac gguguccgca 20  
  
<210> 135  
<211> 23  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 135  
uucaucgcug uuuguuuguu cac 23  
  
<210> 136  
<211> 22  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs  
  
<400> 136  
cctcctcttt tcttttgttt tg 22  
  
<210> 137  
<211> 20  
<212> DNA  
<213> West Nile Virus



<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs  
  
<400> 137  
gcaggtccac ggtgtccgca 20  
  
<210> 138  
<211> 22  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs  
  
<400> 138  
cuuccaucca uucauucc uc 22  
  
<210> 139  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 139  
guuuugucuu ccauccauuc auuc 24  
  
<210> 140  
<211> 22  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs  
  
<400> 140  
gttttgtctt ccatccattc at 22  
  
<210> 141  
<211> 23  
<212> DNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 141  
ctggggtttt gtcttccatc cat 23  
  
<210> 142  
<211> 23  
<212> RNA  
<213> West Nile Virus

<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 142  
cugggguuuu gucuuccauc cau 23

<210> 143  
<211> 23  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 143  
gccuccugg uuucuuagac auc 23

<210> 144  
<211> 30  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(30)  
<223> 2'-OMe nucleotide analogs

<400> 144  
uugccgggcc cuccugguuu cuuagacauc 30

<210> 145  
<211> 24  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs

<400> 145  
cgcguuuuag cauauugaca gccc 24

<210> 146  
<211> 23  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<400> 146  
uccaccucuu gcgaaggacc ucc 23

<210> 147  
<211> 26  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(26)  
<223> 2'-OMe nucleotide analogs  
  
<400> 147  
gucgcaggca gcaccgucua cucaac 26  
  
<210> 148  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 148  
caguccuccu gggguugagu cgca 24  
  
<210> 149  
<211> 23  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs  
  
<400> 149  
gagacgguuc ugagggcuua cau 23  
  
<210> 150  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 150  
cagucccccu gggguugagu cgca 24  
  
<210> 151  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 151  
caguccuccu gggguugagc cgca 24  
  
<210> 152  
<211> 24  
<212> RNA  
<213> West Nile Virus

<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<400> 152  
cagucauccu gggguugagu cgca 24  
  
<210> 153  
<211> 27  
<212> DNA  
<213> Phage T7  
  
<400> 153  
aatttaatac gactcactat agggaga 27  
  
<210> 154  
<211> 15  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(15)  
<223> 2'-OMe nucleotide analogs  
  
<400> 154  
gucaauaugc uaaaa 15  
  
<210> 155  
<211> 14  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(14)  
<223> 2'-OMe nucleotide analogs  
  
<400> 155  
gucaauaugc uaaa 14  
  
<210> 156  
<211> 15  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(15)  
<223> 2'-OMe nucleotide analogs  
  
<400> 156  
ugucaauaug cuaaa 15  
  
<210> 157  
<211> 13  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(13)  
<223> 2'-OMe nucleotide analogs

<210> 158  
<211> 15  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(15)  
<223> 2'-OMe nucleotide analogs

<400> 158  
aaacgcggaa ugccc

15

<210> 159  
<211> 25  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(25)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (21)...(25)  
<223> Molecular beacon arm sequence

<400> 159  
ccgaggucuaa uaugcuaaaa cucgg

25

<210> 160  
<211> 24  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (20)...(24)  
<223> Molecular beacon arm sequence

<400> 160  
ccgaggucuaa uaugcuaaac ucgg

24

<210> 161  
<211> 26  
<212> RNA  
<213> West Nile Virus

<220>

<221> misc\_feature  
<222> (1)...(26)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (22)...(26)  
<223> Molecular beacon arm sequence

<400> 161  
ccgaguguca auaugcuaaa ccucgg

<210> 162  
<211> 23  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (19)...(23)  
<223> Molecular beacon arm sequence

<400> 162  
ggcacgagcc gggcugucgu gcc

<210> 163  
<211> 25  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(25)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (21)...(25)  
<223> Molecular beacon arm sequence

<400> 163  
ccgagaaacg cggaugccc cucgg

<210> 164  
<211> 16  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature

26

23

25

<223> 2'-OMe nucleotide analogs

<400> 164  
gguccuucgc aagagg 16

<210> 165  
<211> 17  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(17)  
<223> 2'-OMe nucleotide analogs

<400> 165  
gguccuucgc aagaggu 17

<210> 166  
<211> 10  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(10)  
<223> 2'-OMe nucleotide analogs

<400> 166  
gguccuucgc 10

<210> 167  
<211> 18  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs

<400> 167  
agguccuucg caagaggu 18

<210> 168  
<211> 18  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs

<400> 168  
gguccuucgc aagaggug 18

<210> 169  
<211> 19  
<212> RNA  
<213> West Nile Virus

<220>

>ature  
<222> (1)...(19)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;400&gt; 169

gguccuucgc aagaggugg

19

&lt;210&gt; 170

&lt;211&gt; 20

&lt;212&gt; RNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(20)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;400&gt; 170

agguccuucg caagaggugg

20

&lt;210&gt; 171

&lt;211&gt; 26

&lt;212&gt; RNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(26)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(5)

&lt;223&gt; Molecular beacon arm sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (22)...(26)

&lt;223&gt; Molecular beacon arm sequence

&lt;400&gt; 171

ccgagggucc uucgcaagag gcucgg

26

&lt;210&gt; 172

&lt;211&gt; 27

&lt;212&gt; RNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(5)

&lt;223&gt; Molecular beacon arm sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (23)...(27)

&lt;223&gt; Molecular beacon arm sequence

&lt;400&gt; 172

ccgagggucc uucgcaagag gucucgg

27

&lt;210&gt; 173

&lt;211&gt; 20



<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(20)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (16)...(20)  
<223> Molecular beacon arm sequence

<400> 173  
ccgaggggucc uucgccucgg 20

<210> 174  
<211> 28  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(28)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (24)...(28)  
<223> Molecular beacon arm sequence

<400> 174  
ccgagagguc cuucgcaaga ggucucgg 28

<210> 175  
<211> 28  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(28)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (24)...(28)  
<223> Molecular beacon arm sequence

<400> 175  
ccgaggggucc uucgcaagag gugcucgg 28

<210> 176  
<211> 29  
<212> RNA

<220>  
<221> misc\_feature  
<222> (1)...(29)  
<223> 2'-OMe nucleotide analogs  
  
<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence  
  
<221> misc\_feature  
<222> (25)...(29)  
<223> Molecular beacon arm sequence

<400> 176  
ccgaggggucc uucgcaagag guggcucgg

29

<210> 177  
<211> 30  
<212> RNA  
<213> West Nile Virus.

<220>  
<221> misc\_feature  
<222> (1)...(30)  
<223> 2'-OMe nucleotide analogs  
  
<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence  
  
<221> misc\_feature  
<222> (26)...(30)  
<223> Molecular beacon arm sequence

<400> 177  
ccgagagguc cuucgcaaga gguggcucgg

30

<210> 178  
<211> 18  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs

<400> 178  
tagacggtgc tgcctgcg

18

<210> 179  
<211> 14  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(14)  
<223> 2'-OMe nucleotide analogs

<400> 179  
cggugcugcc ugcg

14

<211> 12  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(12)  
<223> 2'-OMe nucleotide analogs  
  
<400> 180  
uagacggugc ug 12  
  
<210> 181  
<211> 18  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs  
  
<400> 181  
uagacggugc ugccugcg 18  
  
<210> 182  
<211> 18  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(18)  
<223> 2'-OMe nucleotide analogs  
  
<400> 182  
ugaacaaagc cgcggaugu 18  
  
<210> 183  
<211> 17  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(17)  
<223> 2'-OMe nucleotide analogs  
  
<400> 183  
cucaacccca ggaggac 17  
  
<210> 184  
<211> 24  
<212> RNA  
<213> West Nile Virus  
  
<220>  
<221> misc\_feature  
<222> (1)...(24)  
<223> 2'-OMe nucleotide analogs  
  
<221> misc\_feature  
<222> (1)...(5)

<221> misc\_feature  
<222> (20)...(24)  
<223> Molecular beacon arm sequence

<400> 184  
ccgagcggug cugccugcgc ucgg 24

<210> 185  
<211> 22  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (18)...(22)  
<223> Molecular beacon arm sequence

<400> 185  
ccgaguagac ggugcugcuc gg 22

<210> 186  
<211> 28  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(28)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

<221> misc\_feature  
<222> (24)...(28)  
<223> Molecular beacon arm sequence

<400> 186  
ccgaguagac ggugcugccu gcgcucgg 28

<210> 187  
<211> 28  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(28)  
<223> 2'-OMe nucleotide analogs

<221> misc\_feature  
<222> (1)...(5)  
<223> Molecular beacon arm sequence

&lt;222&gt; (24)...(28)

&lt;223&gt; Molecular beacon arm sequence

&lt;400&gt; 187

ccgagugaac aaagccgcga agucucgg

28

&lt;210&gt; 188

&lt;211&gt; 27

&lt;212&gt; RNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(27)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(5)

&lt;223&gt; Molecular beacon arm sequence

&lt;221&gt; misc\_feature

&lt;222&gt; (23)...(27)

&lt;223&gt; Molecular beacon arm sequence

&lt;400&gt; 188

ccgagcucaa ccccaggagg accucgg

27

&lt;210&gt; 189

&lt;211&gt; 17

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(17)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;400&gt; 189

ccctgcgact caacccc

17

&lt;210&gt; 190

&lt;211&gt; 16

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(16)

&lt;223&gt; 2'-OMe nucleotide analogs

&lt;400&gt; 190

cctgcgactc aacccc

16

&lt;210&gt; 191

&lt;211&gt; 15

&lt;212&gt; DNA

&lt;213&gt; West Nile Virus

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;222&gt; (1)...(15)

&lt;223&gt; 2'-OMe nucleotide analogs

cctgcgactc aaccc

15

<210> 192  
<211> 19  
<212> DNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(19)  
<223> 2'-OMe nucleotide analogs

<400> 192  
aggaggactg ggtgaacaa

19

<210> 193  
<211> 30  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(30)  
<223> 2'-OMe nucleotide analogs

<400> 193  
ccaguccucc ugguugag ucgcagggca

30

<210> 194  
<211> 22  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(22)  
<223> 2'-OMe nucleotide analogs

<400> 194  
cuuuguacac ccaguccucc ug

22

<210> 195  
<211> 36  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(36)  
<223> 2'-OMe nucleotide analogs

<400> 195  
gaucacuucg cagcuuguu cacccagucc uccugg

36

<210> 196  
<211> 23  
<212> RNA  
<213> West Nile Virus

<220>  
<221> misc\_feature  
<222> (1)...(23)  
<223> 2'-OMe nucleotide analogs



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**